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Ajoene ((E-/ Z)-4,5,9-trithiadodeca-1,6,11-triene-9-oxide), a constituent of garlic is known to possess 
in vitro and in vivo anticancer activity based on the presence of a vinyl disulfide as its 
pharmacophore. This thesis reports on the synthesis of dihydroajoenes, a novel set of ajoene 
analogues, containing a saturated double bond, in which the intention was to study the influence of 
removing the double bond on biological activity and metabolic stability, since ajoenes are unstable in 
blood. A divergent synthetic route to 6 new dihydroajoene analogues has been developed in which a 
phenolic hydroxyl group at the disulfide end served as a platform for modulating aqueous solubility. 
The dihydroajoene analogues synthesized retained good in vitro anti-proliferation activity against a 
WHCO1 oesophageal cancer cell line, with the phenol derivative showing the greatest activity, with 
an IC50 of 4.1 µM as about 7-times more active than the parent ajoene. In addition the 
dihydroajoenes were found to be significantly more stable in the red blood cell fraction of mouse 
blood, when compared with ajoene analogues retaining the double bond. This opens up the 
possibility of exploring them as anti-cancer agents in an in vivo setting.  
This thesis also describes a preliminary study towards the synthesis of an ajoene-drug (fludarabine) 
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aq     aqueous 
ar     aromatic 
 
brs     broad singlet     
 
cat.     catalytic 
 
d     doublet 
dd     doublet of doublets 
ddd     doublet of doublets of doublets 
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equiv     equivalents 
EtOAc     ethyl acetate 
EtOH     ethanol 
 
g     grams 
 
h     hours 
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HPLC     high pressure liquid chromatography 
HRMS     high-resolution mass spectroscopy 
 
IDM     Institute of Infectious Disease and Molecular Medicine 
IR     infra-red spectroscopy 
 
J     coupling constants 
 
m     meta 
m-CPBA    meta-chloroperbenzoic acid 
m     multiplet 
min     minute 




mp     melting point 
mg     milligrams 
ml     millilitres  
mmol     millimole(s) 
mol     mole(s) 
Me     methyl 
 
NMR     nuclear magnetic resonance 
 
OMe     methoxy 
o     ortho 
 
p     para 
Pet ether    petroleum ether 
Ph     phenyl 
ppm     parts per million 
pMBCl     para-methoxybenzyl chloride 
q     quartet 
 
RBC     red blood cell 
rt     room temperature 
 
s     singlet 
 
t     triplet 
td     triplet of doublets 
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Chapter 1: Review of Biological and Chemical Aspects of Ajoene 
1.1 Introduction  
 
This thesis describes the synthesis of ajoene analogues designed for a Structure-Activity 
Relationships (SAR) study. The project spans several research fields thus this chapter will give a 
background of some of the interesting aspects of ajoene.  
1.1 Garlic Overview  
 
Garlic (Allium sativum) is a plant species of the genus Allium, to which onion, shallot and chive 
belong.  Garlic has been known throughout history from as early as the ancient Sumerian (2600-2100 
B.C.) and Egyptian civilisations (~1500 B.C.). The use of garlic as a medicinal herb is recorded in the 
oldest preserved medical book, The Egyptian Codex Ebers (Ebers Papyrus).1 Several early civilisations 
came to similar conclusions regarding the therapeutic properties of garlic. The ancient civilisations of 
India, China, Greece, Rome and Egypt used it extensively. Garlic use was common among the 
working class as an agent that could increase endurance, prevent abdominal complications, and 
enhance the cardiovascular and respiratory systems. In ancient Egypt garlic was given to labourers 
working on the pyramids, it was thought to enable workers to work harder and longer hours. Greek 
athletes are reported to have ingested garlic before competing in the Olympics making it the first 
recorded “performance enhancer” in the history of sport.1 
The use of garlic as a culinary and medicinal substance continues to this day. Contemporarily, an 
increased average life expectancy has unearthed a new set of health issues that are age-related. 
There has been questions on the over reliance of synthetic medicines, as opposed to herbal 
medicines, in addressing modern medical concerns. Several studies have shown that a shift to a 
Mediterranean diet reduces the risk of several age-related chronic diseases.2 Garlic is one of the 
plants that is part of the Mediterranean diet and has received resurgent attention in research circles. 
Of particular interest to modern therapies, garlic is claimed to offer protection against cancer, 
cardiovascular disease, platelet aggregation, thrombosis, diseases associated with cerebral aging, 
arthritis, cataract formation; and can rejuvenate skin, improve cardiovascular circulation and 
increase energy levels.3 The biological activity of garlic has been attributed to a group of structurally 




1.3 The Chemistry of Garlic  
Fresh garlic contains mainly water with the bulk of the dry weight being fructose-containing 
carbohydrates (Table 1).3 It also contains protein, fat, fibre, 17 amino acids, at least 33 sulfur 
containing compounds, the elements: germanium  (14 µg/100 g), calcium (50–90 µ g/100 g), copper 
(0.02–0.03 µg/100 g), iron (2.8–3.9 µg/100 g), potassium (100–120 µg/100 g), magnesium (43–77 
µg/100 g), chromium (0.3–0.5 mg/100 g), manganese (0.2–0.6 mg/100 g), boron (0.3–0.6 mg/100 g), 
barium (0.2–1 mg/100 g), aluminium (0.5–1 mg/100 g), sodium (10–22 mg/100 g), phosphorus (390–
460 mg/100 g), zinc (1.8–3.1 mg/100 g) and selenium (15–35 µg/100 g). The fresh garlic clove 
contains various vitamins, namely thiamine (0.25 mg/100 g), riboflavin (0.08 mg/100 g), vitamin C (5 
mg/100 g), nicotinic acid (0.5 mg/100 g) and retinal (15 µg/100 g).4 The medicinal properties and 
biological properties of garlic are attributed to the sulfur-rich compounds present or generated 
when the clove is damaged. 
Table 1: General composition of Garlic, aexcluding protein and inorganic sulfate.3 
Component Amount (fresh weight, %) 
Water 62-68 
Carbohydrates (mainly fructose) 26-30 
Protein  1.5-2.1 
Amino acids: common 1-1.5 




Total sulfur compounds a 1.1-3 
Sulfur 0.23-0.37 
Nitrogen  0.6-1.3 
Minerals  0.7 
Vitamins 0.015 
Saponins 0.04-0.11 
Total oil-soluble compounds 0.15 (whole)-0.7 (cut) 





The earliest chemical studies on garlic were by the German chemist Wertheim in 1844, who isolated 
diallyl (from Allium) disulfide from garlic oil. About five decades later in 1892, Semmler isolated 60 % 
diallyl disulfide, 20 % diallyl trisulfide and a minor component of diallyl tetrasulfide by fractional 
distillation of garlic oil. In 1944 Cavallito reported isolation of an odiferous extract (with antibacterial 
activity), which was coined allicin, by stirring freshly ground garlic clove in 95 % ethanol at 10 °C.5  
The parent sulfur compound found in intact garlic clove is alliin (S-allylcysteine sulfoxide).6 For years 
it remained a mystery as to how alliin was transformed to allicin upon damaging of the clove. In 
1948 Stoll and Seeback reported that garlic cloves contain an enzyme alliinase which is housed in a 
different compartment to alliin and converts alliin into allicin when the clove is damaged (Scheme 
1).7&8 In the first step alliinase catalyses the decomposition of alliin to 2-propenesulfenic acid, while 
in a subsequent reaction two molecules of propenesulfenic acid self-condense to form allicin.  
 
Scheme 1: The conversion of Alliin to Allicin by the action of the enzyme allinase 
Allicin is an odoriferous, unstable thiosulfinate that is slightly soluble in water (2.5 % at 10 °C).5 It 
degrades to give various sulfur compounds that are the consitiuents of crushed garlic preparations 
(the major organosulfides are listed in Fig 1). Allicin is easily transformed into oil-soluble 
organosulfides mainly diallyl disulfide and to a lesser extent diallyl sulfide and diallyl trisulfide. The 
relative amounts of the second-generation organosulfides present in a garlic preparation depends 
on the age and method of preparation of the garlic.6  
Under certain conditions allicin can be transformed into vinyl dithiin or E and Z ajoene.8 Vinyl diithiin 
was first observed from GC-MS analyses of the allicin fraction of a garlic extract.8 (E and Z)-4,5,9-
trithiadodeca-1,6,11-triene-9-oxide (Ajoene, 1) was first reported in the 1980s following the work of 






Figure 1: The major organosulfides found in crushed garlic 
1.4 Ajoene  
 
Ajoene, 1, (Spanish for garlic = Ajo) is a rearrangement product of allicin. It is an organosulfide 
comprised of an allylic sulfoxide and an interesting vinyl disulfide functionality. It was Block and 
Apitz-Castro who first proposed the mechanism by which allicin degrades to ajoene (Scheme 2).10 
 




The degradation of allicin to ajoene according to the proposed mechanism commences with S-
thioalkylation of allicin. In the second step allylsulfenic acid is lost via a Cope-type elimination to give 
a thionium intermediate. In the final step allylsufenic acid re-adds to the thionium intermediate to 
give ajoene (1). In fresh garlic preparations the Z-ajoene isomer is reported to be present in about 
double the abundance of the E-isomer.11 Block and Apitz-Castro reported the biomimetic chemical 
synthesis of ajoene, which involved refluxing a solution of allicin in an acetone-water (3:2) 
suspension.10 The produced material, which was identical to the biological sample, was obtained via 
4 h of centrifugation, then extraction using methylene chloride (DCM) and then the DCM 
concentrate was purified by flash chromatography. Ajoene (1) is reportedly obtained in about 34 % 
yield as a mixture of E and Z isomers (4: 1). 
The early work by Block and co-workers in the 1980s demonstrated ajoene’s ability  to inhibit 
platelet aggregation, and since then there has been an increasing body of evidence reported on the 
biological activity of ajoene by several research groups in the past three decades. Overall ajoene has 
been reported to have antimicrobial, antiobesity, antifungal and anticancer activities.  
1.5 The Biological Activity of Ajoene 
1.5.1 Anti-Thrombotic Activity 
Thrombosis is the formation of a blood clot in a blood vessel, obstructing circulatory blood flow. A 
thrombus (blood clot) can obstruct blood flow to an organ causing severe health complications. 
Physiologically platelet aggregation precedes the formation of a thrombus. Ajoene has been shown 
to inhibit platelet aggregation thus making it a potent thrombotic agent. 
In vitro studies show that ajoene can reversibly inhibit platelet aggregation and activation induced by 
known agonists.12 Ajoene was shown to synergistically potentiate the anti-aggregation properties 
(on human platelets) of the drugs prostacyclin, forskolin, indomethacin and dypiridamole.13 The 
work of Apitz-Castro has shown that ajoene can prevent thrombus formation under highly 
thrombogenic conditions. Under in vivo flow conditions (mimicking small to medium blood vessel 
sizes) ajoene prevented thrombus formation induced by severe vascular damage.12&14 Regarding the 
mechanism by which ajoene inhibits platelet aggregation there has been several suggestions.15&16 
One of the suggestions was that ajoene interacts with a hemoprotein implicated in platelet 
aggregation. Using spectral measurement it was demonstrated that ajoene interacted cooperatively 
with the hemoprotein. The interaction of ajoene with the hemoprotein modified its binding to 




shown that ajoene indirectly inhibits the synthesis of thromboxane A2 (a platelet activator) by 
strongly inhibiting the arachidonic pathway.16 
1.5.2 Anti-Microbial Activity 
Ajoene is a potent inhibitor of various pathogenic microbes of the protozoa, fungal and bacterial 
families, for which it has been shown that ajoene inhibits the growth of various Gram-positive and 
Gram-negative bacteria. The ajoene Minimum Inhibitory Concentration (MIC) was found to be 5 
µg/mL against the gram-positive bacteria: Bacillus cereus, Bacillus subtilis, Mycobacterium 
smegmatis and Streptomyces griseus. Against the gram-negative bacteria, Escherichia coli, Klebsiella 
pneumoniae and Xanthomonas maltophilia, the MICs were found to be between 100 - 160 µg/mL.17 
At concentrations below 20 µg/mL, ajoene inhibits the growth of yeast.17 When fractions of garlic 
extract were studied for antifungal activity, the ajoene fraction was found to exhibit the strongest 
antifungal activity.18 The growth of both the fungi species Aspergillus niger and Candida albicans was 
inhibited by ajoene at concentrations below 20 ug/ml.18 Ajoene also inhibited the growth of the 
human fungal pathogen Paracoccidioides brasiliensis by disrupting the integrity of the fungi’s 
cytoplasmic membrane.19 In botany, ajoene inhibited the germination of plant pathogenic fungal 
spores.20  
Ajoene has also been shown to inhibit phosphatidyl choline synthesis in trypanosomal pathogens, 
ajoene inhibited the proliferation of Trypanosoma cruzi, the causative agent of Chagas' disease.21 It 
has been suggested that the antimicrobial activity of ajoene and similar compounds is dependent on 
the presence of the disulfide bond.  
1.5.3 Anti-Obesity Activity 
Obesity is a chronic disease that is increasing alarmingly worldwide. It is linked with various 
cardiovascular disorders and is a major risk factor for type 2 diabetes. It is characterised by excessive 
fat accumulation that alters health and increases mortality.22 At a cellular level obesity is 
characterised by an increase in the number and size of adipocytes (fat storage cells). A key stage in 
the life-cycle of adipocytes is the differentiation of pre-adipocytes (in adipose tissue) to adipocytes. 
Thus treatments that can regulate the number and size of adipocytes are sought after. Recently it 
was reported that ajoene induces apoptosis in adipocytes.23 At a concentration of 200 µM, ajoene 
decreased the cell viability of adipocytes by approximately 50 %.23 In another study it was shown 
that linoleic acid had a synergistic effect on ajoene-induced adipocyte apoptosis.24 The effect of 





The antitumor effects of garlic have been documented from as early as the ancient Egyptian 
civilisations. Hippocrates widely regarded as the father of medicine, used garlic to treat abdominal 
tumors.1 The anti-carcinogenic effect of garlic has been attributed to allicin, thioallyl constituents 
and their derivatives found within the clove. From herein this review will focus on ajoene and its 
anti-cancer properties.  
1.6 Cancer Overview 
1.6.1 Cancer  
Cancer is a group of diseases characterized by uncontrolled growth and spread (invasion and 
metastasis) of abnormal cells.25 Cancer is the second leading cause of death in the first world, and a 
similar picture is also beginning to emerge in developing countries.25 Approximately 10 million new 
cases of cancer are diagnosed each year.25a In 2012 about 14 million new cancer cases and 
approximately 8.2 million cancer fatalities were reported (WHO).25b 
1.6.2 Treatment of Cancer 
Current cancer chemotherapies target different stages in the cell-cycle. Apoptosis (programmed cell 
death) plays a key role in normal cell physiology. In cancerous cells there is a dysregulation of 
apoptosis. Chemotherapeutics work by targeting fast-dividing cells and inducing apoptosis. 
Chemopreventive drugs are classified as follows26: 
1. Akylating Agents— This class of compounds covalently links to amino, carboxyl, sulfhydryl, and 
phosphate groups of biologically important molecules. The resulting effect being an impaired 
cellular function. An example is cisplatin. 
2. Antimetabolites— These are structural analogues of metabolites involved in deoxyribonucleic 
acid (DNA) or ribonucleic acid (RNA) synthesis. Antimetabolites induce their cytotoxity by 
competing with natural metabolites for key active sites on enzymes or incorporation into DNA or 
RNA, thus impairing DNA or RNA synthesis. Cytarabine and fludarabine are examples. 
3. Natural Products —Several antitumor compounds have been isolated from plants, fungi and 
bacteria.  
a) Antitumor antibiotics 
These are antibiotics produced by bacteria. An example is Bleomycin, its mode of action is 
through insertion into DNA strands resulting in the release of reactive oxidative species (ROS).  
b) Anthracyclines  
Anthracyclines are a class of structurally similar compounds which are produced by the fungus 




their ability to intercalate between DNA base pairs and inhibition of DNA topoisomerases I 
and II. Doxorubicin is an example of this class of drug. 
c) Podophyllotoxins  
These are semisynthetic analogs of compounds naturally occurring in the roots of the 
American plant Mayapple (Podophyllum peltatum). These compounds work by inhibiting 
topoisomerase II. The two common podophyllotoxins are etoposide and teniposide. 
d) Vinca alkaloids 
Class of compounds derived from the periwinkle Catharanthus roseus. Vinca alkaloids work by 
binding to tubulin preventing formation of microtubules an essential component for cell 
division.  
e) Taxanes  
          Are compounds derived from the needles of yew plants (Taxus), characteristic of this class is 
the diterpene backbone. Taxanes promote microtubule assembly and stability causing cell 
arrest in the mitotic stage of the cell cycle. Docetaxel is an example of a well-established 
mitotoxic taxane.  
f) Camptothecin analogs  
These drugs are semisynthetic analogs of camptothecin, an alkaloid isolated from the Chinese 
tree Camptotheca acuminate. Camptothecin analogs inhibit topoisomerase I and interrupt the 
elongation phase of DNA replication. Irinotecan and topotecan are semisynthetic 
camptothecin analogs.  
Despite the progress that has been made in treating cancer over the last three decades, cancer 
incidence is still on the rise, cancer cases are expected to rise from 14 million in 2012 to about 24 
million within two decades.25 The genetic instability and fast-mutating nature of cancerous cells tend 
to leave most drugs inadequate after a few cycles of treatment. This long term ineffectiveness 
coupled with the fact that most chemotherapies have severe side effects, has kept the search for 
more anti-cancer agents a focal point. The design of anti-cancer agents requires the understanding 
of cell physiology and how cancerous cells evade apoptosis.  
 
1.6.3 Eukaryote Cell Cycle 
The cell cycle comprises of five phases: The resting phase G0, Gap 1 (G1), Synthesis (S), Gap 2 (G2) and 
Mitosis (M). In the G0 phase the cell is in a dormant state or resting state and no growth or 
multiplication occurs. Cells in the next stage of the cycle G1, produce mRNA and participate in the 




growing in size and preparing to copy its DNA. The next phase is S, where the cell makes a copy of its 
DNA. Once the cell has made a copy of its chromosomes, it undergoes a second growth phase (G2), 
in which the cell prepares for mitosis. Finally the cell divides and forms two daughter cells (each 
containing a full set of chromosomes) during the M phase. The daughter cells can enter the cycle 
again via G1 or enter a dormant state G0. Progression through the different phases is a highly 
regulated process.27  
Cells have developed a series of cell-cycle checkpoints, which are regulatory pathways that control 
the order and timing of cell cycle transitions and ensure that critical events such as DNA replication 
and chromosome segregation are completed with high fidelity.28 Cell check point loss has been 
implicated in genomic instability and progression to cancer.28 Check points are governed by a group 
of proteins known as cyclins and enzymes called cyclin dependent kinases (CDKs). Cell progression 
from one phase to the other is promoted by the binding of cyclin to its associated kinase thereby 
activating the enzyme.  
To progress from G1 to the S phase there has to be a favourable balance between stimulatory versus 
inhibitory signals towards cell growth. When the balance is favourable towards cell growth and 
multiplication, there is an increase in cyclin D which in turn binds to CDK4 and CDK6 (Figure 2). Once 
the cyclin D-CDK4/6 complex is formed it phosphorylates a growth-inhibitory factor known as 
retinoblastoma protein (pRb). In its hypophosphorylated active state pRb binds to the transcription 
factor E2F but once phosphorylated pRb can no longer bind to the transcription factor.  
 
 
Figure 2: The cell cycle and critical regulators. 30 
 E2F is then free to bind to certain parts of DNA, inducing transcription of several genes that code for 
proteins capable of taking the cell through to the S phase. One of these proteins is cyclin E. Once 
produced cyclin E binds to CDK2 and this complex is responsible for progression from G1 to S phase. 




CDK2 complex is required for the appropriate completion of DNA synthesis in the S phase. Entry into 
mitosis requires activation Cyclin B-CDK1 complex. Progression through the different stages of the 
cycle is blocked by proteins that inhibit activation of the different cyclin-CDK complexes. The 
inhibitory proteins p15 and p16 block the activity of the cyclin D-CDK complex (Figure 2).  
As detailed above the cell-cycle is highly regulated, and progression through one phase of the cycle 
is characterised by an increase in a particular cyclin and activation of CDKs. CDK activation is down 
regulated by inhibitory proteins. When usually tightly regulated cell check points fail cancer is likely 
to result. In breast cancer over production of cyclin D and E results in overactive cyclin-CDK 
complexes.27 The gene that codes for the inhibitory protein p16 is lost in skin melanoma.28 In 90 % of 
all cancers there is oncogenic alteration of cyclins, CDKs and other components of the pRB 
pathway.27 
1.6.4 Apoptosis 
Apoptosis is an energy-dependent organised cell death that involves the activation of a group of 
cysteine proteases known as caspases.29 Apoptosis occurs normally during development and ageing 
as a homeostatic mechanism for the cell populations in tissues and also helps the body rid itself of 
cancerous cells with damaged DNA. The body uses apoptosis as part of its defence mechanism, as an 
immunological response and in response to cell damage by disease or noxious substances.29 The  
two main molecular pathways leading to apoptosis are the intrinsic (mitochondrial) and extrinsic 
(death receptor) pathway. The two pathways are linked and molecules in one pathway can influence 
the other.  
There is a third pathway that uses T-cell mediated cytotoxicity and perforin-granzyme-dependent 
demise of the cell.29 Figure 3 summarises the apoptotic events involved in each pathway. The two 
main pathways are intrinsic and extrinsic as well as a perforin/granzyme pathway. Each pathway 
initiates in response to some stimuli and following a set of energy-dependent molecular events 
activates an initiator (caspase 8, 9, 10). The major convergent point of the caspase-dependent 
pathways is at caspase 3 activation. Once caspase 3 is activated degradation of cellular proteins 





Figure 3: Schematic representation of the apoptotic pathways.29  
The extrinsic pathway (Figure 3) is activated via extracellular receptor-mediated interactions that 
result from cues such as growth factor withdrawal and matrix detachment.30 In the extrinsic pathway 
extracellular ligands (death ligands) bind to tumor necrosis factor receptors (TNF-R, death receptors) 
on the surface of the plasma membrane (Figure 3). An example of a death receptor is FAS and the 
death ligand that binds to it FASL. The binding of a death ligand to its corresponding receptor results 
in a cascade of events that lead to the activation of caspases and cleavage of proteins essential for 
cell survival.  
In the intrinsic pathway (Figure 3) apoptosis occurs in response to intracellular signals such as DNA 
damage or oxidative stress. The signals that lead to intrinsic pathway may be due to toxins, hypoxia, 
viral infection, hyperthermia or free radicals. All these stimuli converge at the mitochondria, causing 
changes in the inner mitochondrial membrane. This results in opening of the mitochondrial 
permeability transition (MPT) pore.31 Loss of mitochondrial transmembrane potential results in the 
release of pro-apoptosis proteins like cytochrome c into the cytosol. Cytochrome c and other 
proteins released from the mitochondria activate the caspase-dependent mitochondrial pathway. 
Cytochrome c binds and activates Apaf-1 forming a complex known as an apoptosome, which then 
recruits and activates procaspase 9. Activation of procaspase 9 leads to caspase 9 activation.  The 
caspases set about destroying the cell’s proteins leading to cell destruction.  
Cytotoxic lymphocytes (CTL) induce their cytotoxicity mainly via the extrinsic pathway. However, 
through a novel mechanism CTL can exert their cytotoxicity on tumor cells and virus infected cells via 




cytoplasmic granules including some structurally related proteases (granzymes). The perforin-
granzyme induced apoptosis strongly activates caspases but is also capable of inducing apoptosis via 
a caspase independent pathway (Figure 3).29  
Caspases have a fatal effect on cells and are thus regulated to ensure apoptosis does not occur 
untimely. The Bcl-2 family of proteins regulates apoptosis. Bcl-2 proteins can either be pro-apoptotic 
(e.g. Bad and Bax) or anti-apoptotic (e.g. Bcl-2 and Bcl-X). In response to apoptotic signals Bax and 
other pro-apoptotic Bcl-2 family proteins translocate to the mitochondrial membrane changing its 
permeability thus enabling cytochrome c release. The anti-apoptotic Bcl-2 family proteins counter 
these effects. A defect in the Bcl-2 family of protein’s regulation system can inhibit apoptosis 
resulting in carcinogenesis. The genes coding for the apoptosis suppressors Bcl-2 and Bcl-X are 
known to be overexpressed in several tumour types.27 
1.7 Anti-cancer Activity of Ajoene 
1.7.1 Anti-mutagenic  
The first aspect of ajoene’s anti-cancer activity concerns its ability to prevent carcinogenesis. 
Consumption of garlic has been shown to reduce the chances of formation of several cancers, which 
has been attributed to the organosulfides present in the clove.31 Ajoene has been shown to inhibit 
mutagenesis, initiated by the mutagens benzo[a]pyrene and 4-nitro-1,2-phenylediamine on S. 
typhimurium, in a dose-dependent manner.32 The mechanisms as to how ajoene inhibits 
mutagenesis are not fully understood. It has been proposed that it could proceed via inhibition of 
cytochrome P450-dependent monooxygenases, which are responsible for carcinogen activation. It 
has also been suggested that the mechanism involves the induction of phase II detoxification 
enzymes, which are responsible for accelerated carcinogen detoxification.32  
1.7.2 Anti-tumour  
Ajoene has been shown to inhibit cell proliferation in a number of malignant cell-lines including 
mammary, bladder, colorectal, hepatic, nasopharyngeal, gastric, prostrate, lung, pancreatic, 
lymphoma, leukemia and skin with an IC50 range of 5 - 41 µM.
33 Scharfenberg and co-workers were 
the first to show the cytotoxicity of ajoene, which was demonstrated on a tumourgenic lymphoid cell 
line derived from a Burkitt lymphoma (BJA-B), with ajoene exhibiting comparably less cytotoxicity on 
the non-tumourgenic control cell line (baby hampster kidney BHK21) and human primary 
fibroblasts.34  
Scharfenberg’s findings on ajoene’s cytotoxicity and selectivity have been substantiated in several 




myeloid leukemia cells (HL60), as well as in peripheral blood mononuclear cells (PBMC) isolated from 
a patient with a chronic myelogenous leukemia.33a Importantly this study showed ajoene was target 
specific, as quiescent and proliferating peripheral mononuclear blood cells isolated from healthy 
donors were not affected by ajoene treatment.33a  
In subsequent work ajoene’s selectivity was demonstrated by Li and co-workers who showed that Z-
ajoene has anti-proliferative activity against various human cancer cell lines (with IC50 values in the 
range 5.2 µM-26 µM) and to a lower extent against normal marsupial kidney cells (PtK2).33b In an 
experiment to evaluate the cytotoxic effects of ajoene, two tumourgenic cell lines were chosen 
promyeloleukemic (HL60) and narsopharyngeal carcinoma (KB), and one normal marsupial kidney 
cell line (PtK2).The cells were incubated with ajoene (1-20 µM) and cell viability measured using a 
MTT-based colorimetric assay. Figure 4 shows the gradual decrease of cell viability with increasing 
concentration of ajoene. HL60 cells were the most sensitive to ajoene cytotoxicity, with only 10 % of 
the cells surviving 48 hours of incubation with 20 µM ajoene, while the KB cells were less responsive 
than the HL60 cells with 30 % of the cells surviving 20 µM ajoene treatment (Figure 4). The PtK2 cells 
were more resistant to ajoene cytotoxicity, with 75 % of the cell fraction viable after a 48 hr 
incubation period. These results demonstrate ajoene’s specificity towards tumourgenic cells. 
 
Figure 4: The effects of Z-ajoene on cell viability of; HL60-●-, KB -■-, and PtK2-Δ-. Cells were exposed to 
increasing concentrations of Z-ajoene (1-20 uM) for 48 hours.
33b 
In vivo ajoene has been found to be effective at treating skin carcinomas both in rodents and in 
humans.33b&c In the study by Li and co-workers Kunming mice were inoculated with transplanted 
tumours: hepatorcarcinoma 22 and sarcoma 180 (S180). After inoculation (24 h later) the mice were 




every day for four weeks. Tumour growth inhibition was measured by weighing of the excised 
tumours. Compared to untreated mice, tumour growth was inhibited by 10 % and 32 % in S180 
implanted mice treated with 4 and 8 mg/kg ajoene respectively. H22 transplanted mice that 
received 2 and 4 mg/kg of ajoene every day reached 34 % and 42 % tumour inhibition. The results 
showed that ajoene treatment retards tumour growth. In a similar mouse-model study, ajoene was 
found to inhibit subcutaneous tumour growth in mice inoculated with B16/BL6 melanoma cells and 
also reduce the occurrence of metastases in the lung by about 90 % compared to untreated mice.33c 
Topical application of ajoene in patients with basal cell carcinoma (BCC) resulted in the reduction of 
tumour size in 81 % of the patients.35 In this study by Tilli and co-workers, a group of 21 patients with 
histologically proven BCC and tumor sizes of maximum diameter 2 cm were selected. The 
carcinomas were treated twice a day by topical application of a 0.4 % ajoene cream (400 mg ajoene, 
0.3 ml polysorbate 80, and 0.3 ml sorbitonoleate in 100 ml 1% carbomeric gel). After six months of 
treatment tumour sizes were measured the results are shown in Figure 5. In 17 of the patients 
ajoene treatment reduced the tumour size, while in 3 patients the tumour size increased and in 1 of 
the patients the tumour size was the same as before treatment (Figure 5).35  
Figure 5: Effect of ajoene on tumour size after topical application in the individual patients.35 
1.7.3 Chemosensitization  
One of the major problems in cancer chemotherapy is the development of drug resistance. 
Chemosensitization is a strategy used to counteract tumour cell’s resistance to a drug, such that 
when administered with the chemosentisization agent the drug becomes effective again. Tumour 




include: increased drug efflux and decreased drug influx, drug inactivation, alterations in drug target, 
processing of drug-induced damage, and evasion of apoptosis (Figure 6).36 Increased drug efflux 
occurs due to the overexpression of resistant drug efflux transporters ( for example MDR1/Pgp and 
BCRP MRPs). Similarly certain intracellular molecules can inactivate drugs such as high levels of the 
thiol glutathione, which is known to inactivate platinum drugs. The third method by which cells can 
become resistant to chemotherapy is the up-regulation of the survival signal with inhibition of cell 
death. This can be through the overexpression of growth factors. As described earlier, the over-
expression of anti-apoptotic proteins (ie Bcl-2) can prevent cell death, and lead to drug resistance,. 
These resistance modifications can lead to the development of drug-resistant cancer cells (Figure 6). 
A successful chemonsensitization agent targets and supresses one or more of the resistance 
mechanisms making drug-resistant cancer cells more susceptible to therapy.36 
 
Figure 6: Overview of proposed mechanisms of drug resistance to cancer chemotherapy. (1) Over- expression 
of a transporter that can efflux the drug, (2) inactivation of the drug by an increased concentration of certain 
intracellular molecules, (3) up-regulation of survival signal and inhibition of cell death, (4) activation of cellular 





In 2004 Hassan reported that ajoene increases the susceptibility of drug-resistant acute myeloid 
leukemia (AML) cells towards fludarabine and cytarabine (leukemia drugs).37 While ajoene did not 
induce apoptosis on its own, in combination with cytarabine or fludarabine ajoene enhanced the 
drugs’ activity. The mode of chemosensitization by ajoene is suggested to occur through targeting 




the anti-apototic protein Bcl-2 and activation of capase 3 in ajoene-treated cells.37 Hassan’s results 
open a new interesting field of ajoene as a chemosensitization agent in cancer treatment, which as 
yet has not been exploited chemically.  
1.8 Signalling Pathways  
 
In the 1990s Dirsch and co-workers showed that ajoene induces apoptosis in human 
promyeloleukemic cells (HL-60) with the generation of intracellular reactive oxidative species 
(ROS).33a A dose- and time-dependent increase in intracellular peroxide was observed when HL-60 
cells were treated with ajoene. The peroxide production was observed using flow-cytometry and 
was evident from as early as 5 min after treatment with ajoene. NF-kB is a factor that has been 
shown to be involved in inducing apoptosis in some cells and also to be activated during oxidative 
stress.33a In the above study Dirsch and co-workers were able to show that there was activation of 
NF-kB when HL-60 cells were subjected to ajoene treatment. Interestingly, when cells were pre-
incubated with the anti-oxidative N-acetylcysteine prior to ajoene treatment, there was significant 
decrease in ROS production and in NF-kB activation. These results showed that ajoene induces 
apoptosis in HL-60 cells using a mechanism that involves ROS production and activation of the 
transcription factor NF-kB.29 &33a 
In a follow up study, Dirsch showed that in the HL-60 cell-line ajoene-induced apoptosis was 
mitochondrial dependent and involved the caspase cascade.33d Using a fluorometric DEVD-cleavage 
assay caspase-like activity could be detected from as early as 4 h after cell exposure to ajoene. This 
caspase-like activity was confirmed following the cleavage of poly(ADP-ribose)polymerase (PARP). 
The PARP protein is a nuclear protein involved in DNA repair, and is a good marker of caspase 
activity during apoptosis. The time-dependent cleavage of PARP and appearance of the typical 85-
kDA fragment after HL-60 cells were treated with ajoene is shown in Figure 7a.  
Interestingly, the apoptosis induction did not require activation of the death-receptor pathway, as 
ajoene induced apoptosis in cloned HL-60 cells devoid of CD95 receptors. Several key 
chemotherapeutic drugs have been shown to express their cytotoxicity by involving the CD95 
receptor system to evoke the apoptotic signal.33 An effort was made to investigate whether the 
apoptotic pathway depended on caspase activity. When cells were pre-incubated with zVAD-fmk 
(broad spectrum caspase inhibitor) prior to ajoene treatment, apoptosis was inhibited. The reliance 
of ajoene-induced apoptosis on caspase activation was measured by DNA analysis using flow 




in zVAD-fmk pre-treated cells remained intact (Figure 7b, right panel). This result showed that 
ajoene-induced apoptosis is caspase dependent. 
 
a)                                                              b) 
Figure 7: Ajoene-induced apoptosis in HL-60 cells is caspase dependent.  a) Caspase like time dependant 
cleavage of PARP; b) the caspase inhibitor zVAD-fmk inhibits ajoene-mediated apoptosis.
33d
 
An integral part of apoptotic pathways that act independently of the death receptors is 
mitochondrial membrane permeabilization (MMP, see 1.5.4). Dirsch et. al. showed that ajoene 
induced MMP and that there was a time dependent release of cytochrome c into the cytosol when 
HL-60 cells were treated with ajoene (Figure 8a).  
 
a)                             b) 
Figure 8: a) HL-60 cells treated with 20 µM ajoene showed timely release of cytochrome c into the cytosol. b) 
HL-60 cells showing localisation of red fluorochrome JC-1 in the mitochondria (Left panel) and ajoene treated 
cells showing the green monomer fluorescence typical of membrane potential loss (right panel).  
Evidence of change in membrane potential was monitored by use of the fluorochrome JC-1, which 
forms red aggregates or green monomers depending on the mitochondrial membrane potential. 
Untreated cells predominantly show localisation of a red fluorescence indicating an intact 
membrane (Figure 8b left panel). As early as  4 hours after exposure to ajoene there was significantly 
less red fluorescence (Figure 8b right panel). After 8 hours the green fluorescence typical of a loss of 




Independently Li et. al. confirmed Dirsch’s findings regarding the mechanism involving mitochondrial 
and caspase cascade activation. Li et. al. went on to show that Z-ajoene-induced apoptosis involves 
cleavage of the anti-apoptotic Bcl-2 protein. The evidence seems to suggest that the intrinsic 
mechanism is the pathway by which ajoene induces apoptosis in cancer cells.  
1.9 Mode of Action and Drug Targets of Ajoene 
Although the anti-cancer activity of ajoene has been linked to the mitochondrial-dependent 
apoptosis pathway, the upstream drug targets and mode of action are still to be elucidated. Ajoene 
and related organosulfides have been shown to induce cell-cycle arrest in the G2/M phase of the cell 
cycle,33b,38 and there have been suggestions that the activity of garlic organosulfides resides in the 
thiol oxidising disulfide bond. In the case of ajoene the disulfide bond is further activated by the 
presence of an adjacent vinyl group.    
Disulfides can act as oxidising agents by thiolating cysteine residues of proteins to form mixed 
disulfides which lead to the disruption of normal protein function and eventual cell death.39 In this 
regard ajoene has been reported to be an inhibitor of thiol-containing enzymes: gastric lipase, 
human glutathione reductase (GR) and T. cruizi trypanothione reductase.40 Gallwitz and co-workers 
showed by crystal structure analysis that inhibition of GR by ajoene resulted in the formation of a 
covalent bond between ajoene and a cysteine residue (position Cys-58) in the enzyme active site. 
The [CH2=CH-CH2-SO-CH2-CH=CH-S] ajoene moiety was incorporated into this newly formed disulfide 
(Scheme 3 (i)). The incorporated ajoene moiety formed a hydrogen bond between the oxygen of the 
sulfoxide and the N-H of alanine-34 in the near vicinity. This interaction was reported to highlight the 
possible biological significance of the sulfoxide, forming important hydrogen bonds within the target 
site. The mixed disulfide formed seems to suggest that the cysteine thiol adds nucleophilically and 






Scheme 3: (i) Reaction of ajoene with cysteine residue on GR;40 (ii) Reaction of ajoene in a cell free 
environment (i.e. in solution) with 1 equivalent of cysteine;
41
 (iii) When ajoene reacts with 2 equivalents of 
cysteine in-solution two products are formed.
41
 Adapted and modified from 
47
. 
This result is mechanistically counter-intuitive as the vinyl-S anion is the more stable leaving group, 
which would indicate that a nucleophilic attack on the allyl-S of the disulfide would be more 
favoured. Importantly a cell-free (in-solution) model reaction of ajoene with cysteine by Lawson and 
Wang was found to form S-allylmercapto-cysteine as the main product (Scheme 3 (ii)), indeed 
showing that the favoured nucleophilic attack occurs on the allyl-S.41 Previously, we have also 
verified this finding in our labs by heating ajoene and cysteine together in ethanol in which the major 
product isolated was the S-allylmercapto-cysteine. In a report by Lawson et al they showed that 
when 2 equivalents of cysteine were reacted with 1 equivalent of ajoene both ajocysteine (3-((3-
(allylsulfinyl)prop-1-enyl)disulfanyl)-2-aminopropanoic acid) and S-allylmercapto-cysteine were 
isolated (Scheme 3 (iii)),41 suggesting that the formation of ajocysteine might occur as a secondary 
reaction. Mechanistically, the ajocysteine is best described as a secondary product that results from 
the primary product (S-allylmercapto-cysteine) undergoing a disulfide exchange with the vinylic-S of 
ajoene (Scheme 3). Overall, the mode of action suggestion here is that ajoene thiolates cysteine 
residues resulting in altered enzyme function that ultimately results in cell death.  
The diverse biological activity ajoene tends to suggest that there might be multiple drug targets, 
there is evidence linking ajoene’s biological activity with its ability to interact and modify proteins 
e.g. -tubulin and 41 integrin.




assembly, PtK2 cells incubated with Z-ajoene underwent a twofold increase in cells blocked in 
mitosis phase compared to untreated cells.33b The microtubule assembly is highly governed in the 
cell and its integrity determines whether cells undergo replication. The microtubule cytoskeleton in 
untreated Ptk2 cells was healthy and intact whilst there was a dose dependent degradation of the 
cytoskeleton in ajoene treated cells as observed using indirect immunofluorescence technique.33b 
Ajoene induced microtubule or tubule disassembly pointing to a possible drug target for this 
compound.33b 
1.10 Summary 
In summary garlic has been used as a culinary and therapeutic agent for over 5000 years. The 
therapeutic effects of garlic have been attributed to the several organosulfides found within the 
clove. When garlic is macerated allicin, an unstable thiosulfinate, is generated which in turn 
degrades to form several organosulfides. Pertaining to this thesis ajoene is one of the more stable 
degradation products from allicin. Ajoene is reported to possess a range of biological activities to 
include antimicrobial, antifungal, antiobesity and anticancer. Regarding its anti-cancer properties 
there is strong evidence suggesting that ajoene induces apoptosis in cancer cells via the intrinsic 
pathway. The drug targets and mode of action of ajoene are not yet fully defined, but there is 
evidence of ajoene possibly thiolating proteins through mixed disulfide formation at susceptible 
cysteine residues. Several studies have shown ajoene’s ability to induce cell arrest in the G2/M phase 
and there is evidence that this might be due to ajoene’s ability to thiolate b-tubulin and to cause 
microtubule disassembly. The work in this thesis was directed towards the Structure-activity 








Chapter 2: Synthetic aspects of ajoene and its analogues 
2.1 Introduction 
 
The only reported synthesis of ajoene is the biomimetic synthesis by Professor Eric Block.9 Ajoene 
can also be obtained from organic extracts of crushed garlic but the yield of ajoene from this method 
is low and the procedure is cumbersome.11 This chapter addresses the synthetic aspects of ajoene 
(regarding Block’s biomimetic synthesis) and the UCT (University of Cape Town) synthesis which was 
developed to access ajoene analogues.  
2.2 Block’s Biomimetic Synthesis 
 
In the 1980’s Block developed a synthetic route to ajoene that mimics the way that it is made in 
nature, by heating allicin in an acetone-water (3: 2) solution. The allicin had been prepared 
beforehand in high yield by the mono-oxidation of commercially available diallyl disulfide using 
peracetic acid (Scheme 4 (i)).  
 
Scheme 4: Block’s biomimetic synthesis of ajoene from allicin. 
Mechanistically, the conversion of allicin to ajoene commences with the acid-catalysed self S-
thioalkylation of allicin yielding a sulfonium ion intermediate and allylsulfenic acid (Scheme 4 (ii)). In 
the next step the sulfonium ion eliminates a molecule of allylsulfenic acid in a Cope-type elimination 
to give a thionium ion intermediate. Allylsulfenic acid then adds to this thionium intermediate via a 




Block’s biomimetic synthesis is reported to only produce ajoene in a low yield of 34 %, although the 
Hunter lab has never been able to reproduce this yield and typically only achieve around 4% yield. 
The other drawback of Block’s synthesis is that it does not allow for variability in the starting 
material as the mechanism demands the presence of an allyl group in the thiosulfinate starting 
material. As can be seen from Scheme 4 above, inevitably an allyl group ends up on the disulfide side 
of the molecule. Thus using this method ajoene analogues containing the sulfoxide and vinyl 
disulfide pharmacophore but with a non-allyl R2 (Figure 9) group cannot be accessed.  
 
Figure 9: The general structure of ajoene analogues. 
A synthetic route to ajoene analogues with variable end groups (R1 and R2) was developed in our 
group a few years ago and several analogues have been accessed as described below.42 
2.3 University of Cape Town Synthesis 
 
Our group has developed a concise four-step synthetic sequence to ajoene analogues, Scheme 5. 
This route allows access to a broad range of terminally substituted analogues.  
Scheme 5: University of Cape Town synthesis of substituted ajoenes. 
 2.3.1 Step 1: Propargylation 
The first step of the synthesis is the propargylation of a thiol, the latter either commercially available 
or accessed via thiourea chemistry. Using thiourea chemistry a variety of thiols can be accessed, via 
refluxing thiourea with the relevant akyl halide (R1X) in acetonitrile to form an isothiouronium salt. 
When the isothiouronium salt is subjected to potassium hydroxide (KOH) at low temperature, 
hydrolysis occurs releasing an alkylated thiol and urea (Scheme 6 step i). Owing to the odiferous 
nature of thiols it is more practical to avoid their isolation and thus the thiol is propargylated in situ 




isolated via an extractive work-up, which is followed by distillation or column chromatography, 
depending on the nature of the R1 group.      
 
Scheme 6: Preparation of propargyl thioether, 2. 
2.3.2 Step 2: Radical addition 
Having obtained the desired propargyl thioether 2 the next step is the key regioselective addition of 
thiolacetic acid to 2, via radical addition to the terminus of 2, using ACCN (1,1`-azobis(cyclohexane-1-
carbonitrile)) as a radical initiator, to form vinyl thioacetate 3. As the Z: E ratio is determined in this 
step the radical addition reaction became the key of the synthetic route. This reaction was studied 
by Kampmeier and Chen in the 1960s, in which they showed that the radical addition of thiolacetic 
acid to 1-hexyne occurs regioselectively and with some level of stereoselectivity.43 Interestingly they 
reported that the favoured stereo-isomer was the Z-isomer. Since the Z-isomer of ajoene is reported 
to be more biologically active than the E-isomer a synthetic route that favours Z-selectivity is 
desirable for ajoene analogues.  
The radical addition mechanism presumably follows the classical initiation, propagation and 





Scheme 7: Radical addition mechanism: (i) initiation, (ii) propagation and termination.  
 At about 85 °C the radical inititator 1,1’-azobis(cyclohexanecarbonitrile) undergoes homolytic 
cleavage that is entropically favoured, to give α-cyano radicals with the release of nitrogen gas 
(initiation). The α-cyano radical then abstracts a proton from thiolacetic acid to form a thiyl radical. 
The propagation step involves the regioselective addition of the thiyl radical to the terminus of the 
propagyl thioether forming a vinyl thioacetate radical, which abstracts a hydrogen from thiolacetic 
acid to regenerate the thiyl radical. The reaction is terminated when two thiyl radicals dimerise to 
form disulfide diacetate. The vinyl thioacetate, 3 is obtained as a mixture of E- and Z-isomers in the 
ratio 2: 3 respectively. The stereoselectivity could be explained on the basis that there is an 
equilibrium between the E- and Z- vinyl thioacetate radicals such that they interconvert. During the 
subsequent hydrogen abstraction from thiolacetic acid the Z- vinyl thioacetate reacts faster as there 
is less steric interference with the approaching thiol acetic, whereas in the E-vinyl thioacetate there 
is a clash with the thioacetate substituent. Thus the Z-isomer is preferred kinetically.  
2.3.3 Sulfenylating agent 
The “right hand side” (-SR2 in Figure 9) of the ajoene analogue is built from a thiosulfonate 
sulfenylating agent (see Scheme 8) that acts as a soft nucleophile towards enethiolate anion. The 
thiosulfonate agent is made beforehand by reacting an appropriate alkyl halide with potassium 
thiotosylate (Scheme 8), in which R2 group of each specific analogue is embedded in the akyl halide 





The thiosulfonate S(SO2)R grouping is structurally analogous to an O-sulfonate ester (e.g. tosylate). 
However, where the O-sulfonate ester makes the adjacent carbon susceptible to SN2 nucleophilic 
attack, the thiosulfonate provides an electrophilic attack site for soft nucleophiles.  
 
Scheme 8: Synthesis of the sulfenylating agent.  
2.3.4 Step 3: S-Sulfenation step  
With the two sides of the ajoene analogue in hand the next step involves coupling the two ends via a 
thiol deprotection and sulfenylation. This was achieved by deprotecting the vinyl acetate 3 to its 
enethiolate using KOH at – 40 ° C and then sulfenylating at low temperature. The deprotection step 
was carried out at a low temperature to avoid geometrical isomerisation of the Z-enethiolate to its 
thermodynamically more stable E-isomer. The sulfenylation occurs on the basis of Hard Soft Acid-
base theory (HSAB) with the soft enethiolate sulfur attacking the soft electrophilic divalent sulphur 
of the sulfenating agent (Scheme 9).  
 
Scheme 9: S-Sulfenylation step 
2.3.5 Step 4: Oxidation  
Having obtained the vinyl disulfide/ sulfide 4, the next step was the chemoselective oxidation of the 
sulfide in the presence of the double bond and the vinyl disulfide. This is achieved by using 1.1 




more nucleophilic sulfide undergoes oxidation to the sulfoxide and importantly both the disulfide 
and the alkene are left intact, Scheme 10.  
 
Scheme 10: Oxidation of vinyl disulfide/ sulfide to target ajoene 5 
2.3.6 Summary 
The UCT synthesis described above is a versatile route for producing terminally substituted ajoenes. 
Several ajoene analogues have been synthesized in our group and analogues relevant to this thesis 
will be discussed in section 2.4. It has been noted that some analogues could be separated into E- 
and Z-isomers, although in other cases the analogues could not be separated and were tested as an 
E/Z-mixture. Furthermore the parent ajoene could not be accessed via this synthetic route, in which 
it was postulated that radical addition to the allyl group occurred during the radical addition step via 
a 5-exo- or 6-endo-trig process.42 Recently Han et. al. reported the synthesis of ajoene using a 
modified University of Cape Town Synthesis, although the details were not provided.44 
2.4 Structure-Activity Relationships of Ajoene analogues 
 
Several ajoene analogues have been synthesized by previous researchers using the UCT synthesis 
(2.3) and in an SAR study several of these analogues were evaluated for their anti-proliferation effect 
(measured using the MTT proliferation assay) on the oesophageal cell line WHCO1, the results are 
summarised in Table 2.45  
Initially the focus was to vary the R1 end group whilst retaining the sulfoxide/disulfide core and 
retaining R2 as an allyl like in the parent ajoene (Table 2, 5a-g). It was noted that analogues 
containing an R1 aromatic group had increased activity when compared to ajoene and on this basis 
the R1 end group was optimised to a p-methoxybenzyl group. Having identified the p-methoxybenzyl 
as the lead R1 terminal, attention was turned to the R2 substituent. Similarly it turned out that 
aromatic substituents increased the activity of analogues (5h-j and 6a) and the p-methoxybenzyl 
substituent returned the most activity. From this SAR study a lead compound in which the terminal 
groups were substituted for p-methoxybenzyl, 6a, was identified with an IC50 of 2.1 ± 0.4 µM, which 




vitro IC50 obtained for the oesophageal cancer clinical drugs cisplatin and 5-fluorouracil, which were 
found to have an IC50 of 9.2 µM and 7.9 µM respectively on the same cell line.
45 
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Figure 10: The advanced lead as identified by SAR study. 
The initial part of the SAR study thus had established that the terminal end-groups (R1 and R2) are 
non-essential for retention of anti-proliferation activity against WHCO1 cells and therefore the next 
part of the structure-relationships analysis now focused on the importance of the vinyl disulfide and 
sulfoxide groups. For this purpose several structural analogues (6b-6f) of the lead 6a were 
synthesized. The MTT assay (Table 3) was used to measure the WHCO1 anti-proliferation activity of 
the compounds.45  
Analogues retaining the disulfide 6a (2.1 µM), 6b (0.7µM) and 6f (16 µM) demonstrated anti-
proliferation activity whilst those in which the disulfide was removed 6c, Z-6d and E-6d were found 
to be inactive. In compound 6f, where the vinyl double was removed, activity dropped by about 8-
fold compared to 6a. From these observations it was hypothesized that the pharmacophore resides 
within the disulfide bond and that the vinyl group labilises the disulfide pharmacophore.  
Compound 6e, in which both the vinyl double bond and sulfoxide group were absent, was not active 
and when the sulfoxide was installed in conjunction with a non-vinylic disulfide in 6f moderate 
activity was restored. This suggests that the sulfoxide has a synergistic effect on the disulfide 
pharmacophore and might be essential for retention of activity when the vinyl bond is removed.45 A 
major part of the work in this current thesis was directed at clarifying this result and probing the 









Table 3: Structureeactivity pharmacophore analysis of E/Z-6a regarding inhibition of WHCO1 cell 
proliferation.45 
Compound no Structure WHCO1 IC50 ± SD (µM) 
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16 ± 3.7 
 
2.4.1 In vivo and Metabolic Studies on Ajoene Analogue 6a 
Owing to its impressive in vitro results 6a was chosen as a candidate for an in vivo evaluation. A nude 
mouse model was used to evaluate the antitumor properties, but due to its high lipophilicity 6a 
could not be administered as an oral dose and so it was delivered via an intralipid vehicle through 
intraperitoneal injection.46 Mice were inoculated with WHCO1 cells (2.5 X 106 cells) delivered via 
subcutaneous injection and the tumours were allowed to develop for 3 days. Thereafter, mice were 




experiment, the mice were killed and the tumours were removed and weighed. Treatment with 6a 
was found to have no effect on tumour growth as treated mice did not exhibit reduced tumour 
sizes.46 Lead 6a was therefore highly effective in vitro at inducing apoptosis in cancer cells but failed 
to reduce tumour cell growth in vivo. It was thought that this failure may be due to either poor 
water solubility of 6a or metabolic instability resulting in poor bioavailability.46  
In order to follow up on the second hypothesis that 6a may be metabolically unstable, a sample of 
the compound was sent to the Department of Pharmacology UCT for pharmacokinetic evaluation. 6a 
was incubated in whole blood, plasma and red blood cell (RBC) fractions of mouse blood at 37 °C for 
2 h. 6a was found to be stable in plasma but the compound rapidly degraded in whole blood and 
RBC fractions (Figure 11). This implies that 6a is interacting with RBCs in mouse blood and this causes 
rapid degradation of the compound ultimately reducing its bioavailability.  
Figure 11: In vitro metabolic stability of 6a in plasma, whole blood and red blood cell fractions.47 
The result obtained is supported by a literature report by Lawson and Wang, in which they found the 
half-life of ajoene in whole blood to be less than 2 min while that of diallyl disulfide (DADS) was 60 
min.41 Both ajoene and DADS possess a disulfide bond, the difference being that in ajoene the 
disulfide is vinylic and this may be the source of metabolic instability. 
Thus with the background of these results the work presented in this dissertation became part of a 
broader project with the aim to improve the water solubility and metabolic stability of the lead 
compound 6a.  
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2.5 Water-Soluble and Metabolically-Stable Ajoene Analogues 
2.5.1 Water-Soluble Ajoene Analogues 
At the onset of the current project several analogues had been synthesized in our group by Mandla 
Mabunda with the aim of addressing the water solubility issues of lead 6a. Four analogues, with 
groups of varying polarity for enhancing aqueous solubility (R) (Figure 12) were accessed using the 
UCT synthesis.  
 
 
Figure 12: The structure of water soluble ajoene analogues. 
The solubility of the analogues was assessed using a turbidimetric aqueous solubility assay and the 
results did indeed support improved aqueous solubility over that of the lead compound 6a. The 
phenol, 7a, and ester, 7c, analogues were the most soluble in aqueous solvent.47 
More importantly, coupled to the increase in water solubility, these analogues all demonstrated 
retention of anti-proliferation activity against the WHCO1 cell line, Table 4. This pleasing result 
demonstrated that it is possible to increase the solubility of analogues without compromising the 
potent anti-proliferative activity. The amide analogue, 7d, was selected for an in vivo assessment, 
but again, this analogue was not found to reduce tumour growth, possibly due to the presence of 









Table 4: Water soluble ajoene analogues anti-proliferative activity against WHCO1 cells. 




2.1 ± 0.4 
7a 
 
1.9 ± 0.8 
7b 
 
3.6 ± 0.04 
7c 
 
1.7 ± 0.9 
7d 
 
7.7 ± 1.7 
 
2.5.2 Metabolically stable Ajoene analogues 
Based on the SAR study of 6a (2.4) it was determined that the disulfide is the pharmacophore in 
ajoene analogues and that the vinyl bond enhances the activity. We hypothesize that the vinyl 
double may render 6a to be unstable in whole blood thereby preventing it from reaching the tumour 
and rendering the compound inactive when delivered by IP injection in vivo. The aim of this project 
was to synthesize the more water soluble ajoene analogues but lacking the vinyl group as a 
comparison with analogues 7a-d the targets became 8a-d as shown in Figure 13.  
 





This study aimed to address two questions:  
1) Is the double bond essential for activity? And 
2) Does its removal aid in increasing metabolic stability. 
2.6 Objectives  
 
Synthesize a small library of ajoene analogues lacking the vinyl double bond (dihydroajoenes, Figure 
13).  
Biologically evaluate this library of compounds. 
Carry out a study towards synthesis of an ajoene-drug conjugate for chemosensitization evaluation. 









Chapter 3: Results and Discussion 
3.1 Dihydroajoenes 
 
3.1.1 Dihydroajoene Synthesis 
At the onset of this project four analogues of ajoene with aqueous-solubility enhancing groups had 
been synthesized (Chapter 2, Table 3), and though very active in vitro we were soon to learn that the 
analogues were ineffective in vivo. Thus the synthesis of the dihydroajoenes (Figure 13) began with 
the aim of evaluating whether we could improve metabolic stability, by removing the vinyl bond, 
while retaining anti-cancer activity in these analogues.  
Figure 13: Structure of dihydroajoene targets 
3.1.2 Synthetic Rationale  
A retrosynthetic analysis of a synthetic route to the dihydroajoene core is shown in Scheme 11. The 
synthetic route is a divergent one with the different aqueous solubility enhancing groups (R) being 
installed at the end of the sequence. It was imagined that chemoselective oxidation of the coupled 
product, 13a, would be possible at the anticipated more electron-dense benzyl sulfide to give the 
sulfoxide, 8a. Using previously established methodology 13a could be obtained in a two-step one-pot 
synthesis from the commercially available p-methoxybenzyl chloride, 1,3-propanedithiol and a 
previously prepared thiotosylate 11, prepared via an SN2 reaction between potassium thiotosylate 
and iodide 10. In turn, 10 was envisaged to be made from the commercially available ester methyl 4-






Scheme 11: Retrosynthetic analysis of the dihydroajoene synthesis. 
3.1.3 Thiotosylate Sulfenating Agent, 11 
The synthesis commenced with preparing the sulfenating agent for the disulfide end (right hand 
side) of the molecule. Starting from commercially available methyl 4-hydroxyphenylacetate previous 
work had shown that 11 could be obtained in relatively high yield over three steps. 47  
Scheme 12: Synthetic route to sulfenating agent 11 
3.1.3.1 Alcohol, 9 49 
Methyl 4-hydroxyphenylacetate was added to a stirring mixture of LiAlH4 (2 equiv) in dry THF at – 78 
°C and full conversion of the ester to the alcohol, 9, was observed on TLC after 2 h, with 9 appearing 




down to 3. After the reaction work-up and chromatography the solid residue was recrystallized from 
a minimum amount of EtOAc and hexane to give 9 as a white powder in 82 % yield.  
The 1H NMR spectrum of 9 revealed a broad singlet at 8.00 ppm corresponding to the phenolic 
hydrogen, an AA’BB’ system at 6.74 (H-2) and 7.05 (H-3) corresponding to a p-disubstituted aromatic 
system and a broad singlet at 3.53 ppm corresponding to the newly formed hydroxyl group. The 13C 
NMR spectrum confirmed reduction by virtue of the disappearance of the carbonyl resonance. 
Interestingly, C-2 (116.0) was more shielded than C-3 (130.8), which is explained by the mesomeric 
effect of the oxygen atom donating a lone pair of electrons into the -system.  
3.1.3.2 Iodide, 10 50 
Having obtained the alcohol, 9, in good yield the next step was conversion of the primary alcohol to 
its corresponding alkyl halide. Several methods can be used to achieve this transformation including 
activation to a sulfonate ester followed by displacement by tetrabutylammonium Iodide to afford 
the iodide; Lewis Acid activation with BF3 in Et2O; reaction with SOCl2; the combination of P4 and I2. 
After careful consideration we decided to use triphenylphosphine and iodine to convert the primary 
alcohol into an iodide. This methodology tends to give rapid, clean conversion and the reaction can 
easily be followed on TLC. The reaction is very similar to the Appel reaction were triphenylphosphine 
and tetrahalomethanes (CCl4, CBr4) are used to convert primary or secondary alcohols into alkyl 
halides. The reaction was performed by dissolving I2 (1.2 equiv) and PPh3 (1.2 equiv) in dry THF and 
then adding the alcohol (1.0 equiv) and imidazole (1.2 equiv), the latter to neutralise the HI by-
product formed. The reaction was allowed to proceed overnight at room temperature and the 
product 10 was isolated as a white powder in 91 % yield.  
The synthesis of 10 was confirmed using 1H and 13C NMR spectroscopy. The 1H NMR spectrum 
revealed the disappearance of the hydroxyl proton peak which was at 3.53 ppm previously in 9, 
while the H-6 protons were now further upfield at 3.31 ppm due to the lower deshielding effect of 
iodine. The aromatic region showed a characteristic AA’BB’ system (apparent doublets) at 6.78 (H-2) 
and 7.06 (H-3) still intact. Similarly the broad singlet at 4.87 ppm confirmed that the phenolic OH 
had been left intact, while the 13C NMR spectrum showed C-6 shift upfield from 64.3 ppm to 6.2 
ppm, confirming the change in functional group from the very electronegative second-period 






3.1.3.3 Phenolic Thiotosylate tether, 11 
The thiotosylate sulfenylating agent 11 was obtained by stirring the iodide, 10, with potassium 
thiotosylate (3.0 equiv) in DMF for 2 h (Scheme 13). Using column chromatography 11 was isolated 
as a golden-brown oil in 91 % yield.  
 
Scheme 13: Synthesis of phenolic thiotosylate tether 11. 
The product was fully characterised using IR, HRMS, 1H and 13C NMR spectroscopy. Its IR spectrum 
revealed the presence of a tosylate group (-RSO2R-) at 1228 cm
-1
 and also an aromatic phenol (ArOH) 
at 3152 cm-1. The 1H NMR spectrum revealed a characteristic AA’BB’ system (apparent doublets) at 
6.74 ppm (H-10) and 6.95 ppm (H-9), and 7.34 ppm (H-3) and 7.81 ppm (H-4) for the aromatic 
hydrogens confirming the presence of two p-substituted aromatic rings. The distinctive methyl 
singlet (H-1) on the ring and a broad phenolic hydroxyl singlet were observed at 2.45 ppm and 3.38 
ppm respectively. The two methylene protons H-6 and H-7 were observed as triplets integrating for 
two protons each at 2.83 ppm and 3.18 ppm respectively. The 13C NMR spectrum revealed all the 8 
aromatic carbon signals expected in the region 114 -155 ppm, while the methyl resonance could be 
observed upfield at 21.8 ppm and the two methylene carbons C-6 and C-7 observed at 34.4 ppm and 
37.6 ppm respectively. The downfield shift of the C-6 methylene (6.4 ppm to 34.4 ppm) provided 
substantial evidence for the formation of a C-S bond. High-Resolution Mass Spectrometry confirmed 
the structure of 11, with the dominant molecular ion being found at 309.0615 [M+ H] +; C15H17O3S2 
requires 309.0619.  
3.1.4 Mono-PMB thiol, 12 
3.1.4.1 Two-step, one-pot synthesis of coupled product 13a 
With the thiotosylate, 11, in hand attention was focused on obtaining the coupled product 13a, 
which was envisaged could be obtained from a two-step, one-pot synthesis reaction involving the 
monoalkylation of 1,3-propanedithiol by p-methoxybenzyl chloride (pMBCl) followed by a second 




Scheme 14: Two step, one-pot synthesis of coupled product 13a 
In the initial approach, 1,3-propanedithiol (1.1 equiv) and potassium hydroxide (1.3 equiv) were 
dissolved in degassed EtOH and stirred for 5 min at room temperature, and then pMBCl (1.0 equiv) 
dissolved in EtOH was added to the reaction dropwise via a syringe over 1 h. After stirring the 
reaction mixture for 2 h another 2 equivalents of KOH was added followed by thiotosylate 11 (1.0 
equiv) dissolved in EtOH. After stirring for 3h the desired product 13a was isolated in 47 % yield. This 
one-pot methodology was more desirable as it avoided isolation of the odiferous thiol 12. However, 
several experiments revealed that the first step was sluggish and that inevitably alkylation occurred 
on both sulfurs of the dithiol to give the undesired di-p-methoxybenzylated bis-sulfide as a 
competing product. Several efforts to manipulate the reaction conditions to achieve mono S-
alkylation resulted in even lower yields. At this point it was decided to optimise the two reactions 
independently, i.e. optimally synthesise and isolate the mono-sulfide and then experimentally find 
the optimal conditions for coupling the remaining thiol group into the thiotosylate 11.  
3.1.4.2 Mono-PMB thiol, 12 
The studies carried out in 3.1.4.1 revealed that bis-alkylation of the 1,3-dithiol occurred, and in some 
instances the ratio of mono- : di-alkylated product was 1 : 1 (by TLC analysis). Furthermore, 
chromatography of the reaction residue was laborious as the product and by-product had a similar 
Rf on TLC (0.30 and 0.25 respectively in 1 % EtOAc: Hexane). Given these results it was decided to 
keep the concentration of pMBCl at one equivalent, with a slight excess of 1,3-propane dithiol (1.1 
equiv) and also to try the alkylation at 0 °C in order to minimize formation of the di-alkylated 
product. Indeed this paid off as at 0 °C the formation of the di-alkylated product was minimised. 
Thus, 1,3-propanedithiol (1.1 equiv) was dissolved in degassed methanol, KOH (1.3 equiv) was added 
to the reaction and the solution stirred for 5 min at 0 °C. This was followed by addition of a solution 
of pMBCl (1 equiv) in methanol which was slowly added to the reaction dropwise over 30 minutes. 
Using this optimised method the desired thiol 12 was isolated by column chromatography as a highly 





Scheme 15: Synthesis of Mono-PMB thiol 12 
12 is a new compound that was fully characterised using IR, MS, HSQC, 1H and 13C NMR 
spectroscopies. Its 1H NMR spectrum revealed a diagnostic thiol triplet at 1.31 ppm, H-2 as a quintet 
at 1.84 ppm, H-3 as a triplet that coupled with H-2, H-4 as a singlet at 3.66 ppm and in the aromatic 
region an AA’BB’ system (apparent doublets) at 6.84 (H-7) and 7.20 (H-6). The H-1 protons 
experienced coupling with the sulfhydryl hydrogen resulting in the appearance of H-1 as a quartet at 
2.58 ppm. The 13C NMR spectrum showed interesting features, with C-1 and C-3 observed upfield at 
23.6 ppm and 29.7 ppm indicating a shielding effect by the neighbouring sulfurs, while the C-2 
methylene was further downfield at 33.2 ppm. Also, the benzylic C-4 was observed at 35.8 ppm, 
again rather shielded for a substituted benzyl, due to the neighbouring sulfur. The methoxy signal 
was observed as expected at 55.4 ppm and all aromatic peaks (4) were found in the region 114.0-
159.0 ppm. The methylene protons were all co-related to their respective carbons using HSQC.  












3.1.5 Coupled product, 13a 
Having obtained 12 in a decent yield, the next step was the disulfide formation step involving 
thiotosylate, 11. Our initial approach mirrored the second step of the one-pot synthesis discussed in 
3.1.4, which involved dissolving 12 (1.2 equiv) and KOH (2 equiv) in ethanol and then adding 
phenolic thiotosylate 11 (1 equiv) to the reaction at room temperature. The reaction was complete 
in 5 mins according to TLC, although the desired product 13a was isolated in a poor yield of only 40 
%. It was postulated once formed, that the product could be undergoing a secondary reaction 
presumably via disulfide exchange. Several conditions were explored experimentally to optimise the 
reaction outcome, which are summarised in Table 5.  
Scheme 16: Reaction to coupled intermediate 13a 
During the optimisation process it was noted that lower temperatures resulted in higher yields of 
13a (Table 5), with presumably the secondary reaction being much slower at these temperatures. 
Similarly the reaction yields improved drastically when the phenolic tosylate, 11, was added in 
excess (Table 5, entry 6-8), and this supported the view that remaining thiol was reacting with the 
newly formed product, 13a, to give secondary products. The reaction occurred rapidly using KOH, so 
the moderate base triethylamine was used instead which presumably reduced the ionicity of the 
phenoxide formed based on the change in cation from potassium to triethylammonium.  
Table 5: Optimisation of reaction to coupled intermediate 13a 
Entry Thiol, 12 
(equiv) 
Base Tosylate 11 
(equiv) 
Temperature Yield of 13a 
1 1.2 KOH (2 equiv) 1 RT 40 % 
2 1.2 KOH (2 equiv) 1           0 °C  40  % 
3 1.2 KOH (2 equiv) 1         - 20 °C ~ 40  % 
4 1.2 KOH (2 equiv) 1         - 78 °C 50  % 
5 1 KOH (2 equiv) 1.2          -20 °C 24   % 
6 1 KOH (2 equiv) 1.2          - 78 °C 60   % 
7 1 NEt3(2.5 equiv) 1.2          - 78 °C 60   % 







From this study we found that the conditions involving excess of 11 (2.5 equiv), triethylamine (1.5 
equiv) and a low temperature of – 78 °C gave an excellent yield of 88 % (entry 8) of 13a. 
13a is a new compound that was fully characterised using IR, HRMS, HSQC, 1H and 13C NMR 
spectroscopy. Its 1H NMR spectrum revealed the presence of a double pair of apparent doublets in 
the aromatic region at 6.75 (H-3’) and 7.05 ppm (H-2’), and 6.84 (H-3”) and 7.22 ppm (H-2”), 
confirming the introduction of a second p-substituted-aromatic moiety. The distinctive methoxy and 
phenolic protons were observed as singlets at 3.79 and 4.77 ppm respectively, the methylene 
protons H-3, H-2, and H-4 were observed at 1.93, 2.51 and 2.73 ppm respectively, while H-5 and H-6 
were observed as a broad singlet at 2.89 ppm which was unexpected, but may be explained as a pair 
of overlapping triplets that did not resolve well. Synthesis of 13a was confirmed by High-Resolution 
Mass Spectrometry, in which the major molecular ion was found at 379.0860 [M-H]+; C19H23O2S3 
requires 379.0866. The biological evaluation of 13a will be discussed in Chapter 4. 
 














Figure 16: The HRMS of 13a 
3.2 Dihydroajoenes with water-solubility enhancing groups  
 
As described in section 3.1.1 one of the objectives of this project was to synthesize ajoene analogues 
with water-solubility enhancing groups (WSGs) (see Figure 13).  
We envisaged a divergent synthesis involving various alkylations of the phenol-sulfoxide 8a to install 
the various WSGs as the last step (Scheme 11). Using this sequence, as described later, we could 
obtain the ester analogue 8c relatively easily (see section 3.2.5). However, the two analogues, 
namely acetate, 8b, and amide, 8d, proved difficult to obtain. In the case of 8d the product was 
obtained with an inseparable impurity so could not be used further. Due to these unexpected issues 
the synthetic sequence was altered such that derivatization of 13a preceded the oxidation step 






Scheme 17: Alkylation of the coupled product 13a 
3.2.1 Trisulfide-acetate 13b 
The first derivative chosen was the acetate 13b which could be easily prepared by a standard 
acetylation using acetyl chloride with triethylamine in dichloromethane (DCM) as solvent. The 
reaction was complete after only 1hr, and the less polar acetate 13b was isolated as yellow oil in a 
modest yield of 64 %. As before, 13b is a new compound that was fully characterised using IR, HRMS, 
HSQC, 1H and 13C NMR spectroscopy. Its IR spectrum gave a carbonyl absorption at 1750 cm-1, while 
the 1H NMR spectrum revealed a new methyl peak at 2.30 ppm corresponding to the acetyl methyl 
H-6’, together with disappearance of the OH singlet which was at 4.77 ppm in 13a. The 13C NMR 
spectrum confirmed the presence of the acetyl group by virtue of a new ester carbonyl (C-5’) at 
169.5 ppm and a methyl C-6’ at 21.1 ppm.  All protons were correlated to their carbon assignments 
with the aid of HSQC and the synthesis final confirmation came from High-Resolution Mass 











Figure 17: The HRMS of trisulfide-acetate 13b 
















3.2.2 Trisulfide-ester 13c 
For the next derivative, 13c, involving alkylation with methyl 2-bromoacetate the base was changed 
to potassium carbonate (1.5 equiv) in dry acetonitrile, in order to promote the more difficult SN2 
reaction (compared to the SNAc of the acetylation) via a more ionic phenoxide ion (K
+). The reaction 
mixture was stirred under N2 at 45 °C overnight, and the desired trisulfide-ester, 13c, was isolated as 
a dark-yellow oil in 78 % yield. 13c is a new compound that was fully characterised using IR, HRMS, 
HSQC, 13C and 1H NMR spectroscopies. Its IR spectrum revealed an absorbance band at 1750 cm-1 
corresponding to a carbonyl absorbance, confirming the presence of the ester carbonyl. The 1H NMR 
spectrum of 13c when compared to that of 13a revealed distinctive new singlets for H-7’ (Me) and H-
5’ (CH2) at 3.79 and 4.61 ppm respectively. Similarly, the 
13C NMR spectrum also confirmed the 
introduction of the methoxycarbonylmethylene moiety , with the C-6’ carbonyl observed at 169.7 
ppm, and the C-7’ and C-5’ resonances at 52.5 ppm and 65.7 ppm respectively, the latter more 
deshielded by both oxygen and carbonyl groups. Finally, synthesis of 13c was confirmed using High 
Resolution Mass Spectroscopy (HRMS), in which the major molecular ion was found at 475.1047 
[M+Na]+; C22H28NaO4S3 requires 475.1047. HRMS was used because combustion analysis generally 
does not give accurate enough results with oils.  















Figure 20: The High-Resolution Mass Spectrum of 13c 
3.2.3 Trisulfide-amide 13d 
The final derivative, primary amide 13d, was chosen in view of the amide’s ability to hydrogen bond 
to water and hence significantly improve aqueous solubility. As with ester 13c, it could be accessed 
via SN2 alkylation with chloroacetamide in dry acetonitrile using the potassium phenoxide of 13a 
generated using potassium carbonate as base. Stirring the heterogeneous reaction at 45 °C for 1hr 
resulted in complete conversion and following a conventional work-up and purification resulted in 
isolation of 13d as a white powder in a good yield of 77 %. 13d was fully characterised using IR, 
HRMS, HSQC, 1H and 13C NMR spectroscopy. Compared to 13a the 1H NMR of 13d revealed 
distinctive new peaks as two broad singlets at 6.54 and 6.00 ppm corresponding to the non-
equivalent amidehydrogens, as well as a sharp singlet at 4.47 ppm corresponding to the deshielded 
methylene protons H-5’. The H-2’ and H-3’ aromatic protons resonated slightly more downfield at 
7.14 ppm and 6.85 ppm respectively (from 7.05 and 6.75 ppm in 13a), presumably due to the 
inductive elecron-withdrawing effect by the amide. Similarly, the 13C NMR spectrum revealed a new 
carbonyl peak at 171.2 ppm and the C-5’ methylene was found relatively downfield at 67.5 ppm. 
Finally, the synthesis of 13d was confirmed by High-Resolution Mass Spectrometry, with the 










Figure 21: The 1H NMR spectrum of trisulfide-amide 13d 
Figure 22: HRMS of trisulfide-amide 13d 
Several attempts were made to regioselectively oxidise the trisulfides 13b-13d to their 
corresponding sulfoxides. However, the reaction of the trisulfides with m-CPBA (1.2 equiv) resulted 







oxidation occurring on one of the disulfide sulfurs. The instability of the products could have been 
due to the production of thiosulfinates. Why this only occurs for the substituted dihydroajoenes 
could not be rationalised, as 13a was oxidised without any major issues. 
3.2.4 Phenol-Sulfoxide, 8a 
In the final step to obtain the dihydroajoene core, sulfide 13a was regioselectively oxidised to 8a 
using 1.2 equivalents of m-CPBA at -78 °C, allowing 8a to be isolated as a colourless oil in 72 % yield. 
At -78 °C the oxidation occurs exclusively on the benzylic sulfur as it is presumably the more 
nucleophilic sulfur, with the disulphide sulfurs being less nucleophilic due to mutual electron 
withdrawal. A mechanism for the reaction is shown in Scheme 18, in which a lone pair on sulfur 
attacks the terminal oxygen of m-CPBA (which is electrophilic due to the inductive effect of the 
benzoic acetate) releasing the m-chlorobenzoate anion and giving a sulfonium cation. The reaction is 
completed when the benzoate anion abstracts a proton from the sulfonium cation forming the 
sulfoxide 8a and m-chlorobenzoic acid as a by-product. 
Scheme 18: Chemoselective oxidation of 13a to the phenol-sulfoxide 8a. 
Sulfoxide 8a is a new compound that was fully characterised using IR, HRMS, HSQC, 1H and 13C NMR 
spectroscopy. Its IR spectrum showed an absorbance at 1265 cm-1 confirming the presence of a 
sulfoxide. The 1H NMR spectrum provided evidence for oxidation at the benzylic sulfur, with the H-1 
protons observed as a diastereotopic pair of AB doublets at 3.95 and 4.00 ppm, which was a 
considerable shift downfield from 3.67 ppm in 13a. The H-2 and H-4 methylene protons were 
observed as a multiplet at 2.69 ppm, also revealing a downfield shift for the H-2 protons from 2.51 




environment around C-1 resulting in the H-1a and H-1b (see Scheme 18 for numbering) protons 
appearing as diastereotopic doublets due to geminal coupling. The H-2 hydrogens are also 
diastereotopic; however, due to the overlap of shifts with H-4 protons, the expected pair of AB 
triplets for H-2 could not be observed. The 13C NMR spectrum of 8a revealed C-1 at 57.8 ppm and C-
2 at 48.9 ppm, also significantly deshielded compared to those for 13a (Table 6) again confirming 
oxidation at the benzylic sulfur. Interestingly, C-3 (22.3 ppm) and C-1” (121.4 ppm) were significantly 
more upfield than in 13a, revealing that the sulfoxide has a peculiar shielding effect on the β-carbon 
positions. Finally, the synthesis of 8a was confirmed by High Resolution Mass Spectrometry, the 
parent molecular ion was found at 397.0966 [M+ H] +; C19H25O3S3 requires 397.0966. The purity of 8a 
was determined to be greater than 95 % using Liquid-chromatography Mass Spectrometry and its 
biological evaluation will be discussed in Chapter 4. 
 
Figure 23: Chirality of the sulfoxide, 8a. 
Table 6: 13C NMR spectrum shifts for compounds 8a and 13a  
Assignment Phenol 13a (C-13 
Shifts/ppm) 
Phenol-Sulfoxide 8a (C-13 
Shifts/ppm) 
C-1 35.9 57.8 
C-2 29.9 48.9 
C-3 28.6 22.3 
C-4 37.7 37.3 
C-5 35.0 34.9 
C-6 40.7 41.1 
OMe 55.5 55.5 
C-1’ 132.4 131.7 
C-1” 130.5 121.4 
C-2’ 129.9 129.9 
C-2” 130.0 131.4 
C-3’ 115.5 115.8 
C-3” 114.1 114.7 
C-4’ 154.1 154.9 






Figure 24: High-resolution Mass Spectrum for the phenol-sulfoxide, 8a 
















3.2.5 Ester-Sulfoxide, 8c 
As mentioned in section 3.2, the one sulfoxide (dihydroajoene) derivative that could be accessed in a 
divergent manner from the parent phenol-sulfoxide 8a was ester-sulfoxide 8c, whose synthesis was 
achieved via phenoxide alkylation in dry acetonitrile with methyl bromoacetate at 45 °C. The 
reaction was complete in 1 h and using column chromatography, the product being isolated as a 
yellow oil in a good yield of 77 %. 
Scheme 19: Alkylation of Phenol-sulfoxide 8a to the Ester-sulfoxide 8c 
Compound 8c, was characterised using IR, HSQC, LCMS, 1H and 13C NMR spectroscopy. Its IR 
spectrum revealed an absorption at around 1750 cm-1 corresponding to a carbonyl group. Compared 
to 8a, the 1H NMR spectrum of 8c revealed two new singlets at 3.55 ppm and 4.55 ppm 
corresponding to H-7’ and H-5’ respectively, while the aromatic region was slightly altered from the 
starting material with the H-2’ protons appearing further downfield at 7.10 ppm (7.01 ppm in 8a). 
The 13C NMR spectrum confirmed the incorporation of the ester, by virtue of a new ester carbonyl 
(C-6’) at 169.6 ppm, also with two new singlets for C-7’ and C-5’ 52.4 ppm and 65.6 ppm respectively 
similar to resonances for the sulfide analogue 13c. Finally, synthesis of 8c was confirmed using Liquid 
Chromatography-Mass Spectrometry (LCMS), the major molecular ion being found at 491.0 [M-Na]+; 
C22H28NaO5S3 requires 491.1. LCMS was used (in place of HRMS) as it was important to determine 
the purity of the sample before proceeding with the biological evaluation. 
Compound 8c was not evaluated biologically, as there was evidence of minor degradation on TLC 
with a faint less polar spot observed after storing the compound at - 20 ° C for 24 h. Interestingly, 
after 5 months of storing 8c at -20 °C degradation was more evident on TLC but could not be 
observed by either 1H or 13C NMR spectroscopy. However, using LCMS the purity of this sample was 










The oxidation of the trisulfides 13b, 13c and 13d resulted in unstable products which were difficult 
to isolate. Thus the sulfoxides, 8b and 8d were not pursued further.  
3.3 Studies towards the synthesis of an ajoene chemosensitization agent 
 
3.3.1 Introduction  
As described in section 1.6.3, ajoene has been shown to enhance the activity of the leukaemic drugs 
cytarabine and fludarabine, and this area of ajoene-induced chemosensitisation has not been fully 
explored. A study was thus initiated towards the development of an ajoene-fludarabine conjugate. 
The target conjugate would have ajoene and fludarabine linked by a biologically hydrolysable bond 
in order to release the two drugs in the hope of achieving synergism. Previous work had shown that 
the ajoene analogue, 7a, with a phenol substituent retained very good cell anti-proliferation in vitro. 
It was envisaged that the phenolic hydroxyl group would provide a suitable site for attachment of an 
electrophilic position on a linker, which would link at the other end to the phosphate functionality of 
commercially available fludarabine via a phosphate ester bond using a methodology reported by H. 
Brachwitz.48a The synthons in this plan are shown in Scheme 20.  













Scheme 20: Connection chemistry of the ajoene-fludarabine conjugate 
3.3.2 Synthesis of ajoene 7a 
The first task towards an ajoene-fludarabine conjugate was the synthesis of the ajoene analogue 7a. 
A retrosynthetic analysis of 7a is shown in Scheme 21, based on the UCT synthesis described in 
section 2.3, and involving thiotosylate, 11, developed for the dihydroajoene synthesis.  
 
Scheme 21: Retrosynthetic analysis of ajoene analogue 7a 
3.3.2.1 Propargyl thioether, 14 
The synthesis of 7a began with the preparation of the propargyl thioether 14, via in situ 
propargylation of p-methoxybenzyl thiol. The latter was accessed by refluxing commercially available 
p-methoxybenzyl chloride (1.0 equiv) and thiourea (1.2 equiv) in acetonitrile (Scheme 22 (i)) 




Scheme 22: Synthesis of propargyl thioether, 14 
Thiourea is more nucleophilic on the sulfur due to the donation of lone pairs by the neighbouring 
nitrogens into the thiocarbonyl, thus when refluxed with p-methoxybenzyl chloride the sulfur attacks 
the benzylic carbon (Scheme 22 (i)). The resulting isothiouronium salt was isolated using a cold 
filtration in a crude yield of 91 %, which was used without further purification. The latter (1.0 equiv) 
was then dissolved in degassed methanol containing KOH (2.5 equiv) at -20 ° C. After stirring the 
solution for 2 h the reaction temperature was allowed to rise to 0 °C at which point propargyl 
bromide was added. Addition of the hydroxide anion resulted in hydrolysis of the saIt, releasing urea 
and a benzyl thiol (Scheme 22 (i)). Hydrolysis of the isothiouronium salt is entropy-favoured due to 
the realease of urea. It was important to use 2.5 equiv of KOH for the hydrolysis and the quenching 
of the HBr by-product formed in the propargylation step. Following a conventional work-up the 
propargyl thioether, 14, was isolated as a gold-coloured oil in 90 % yield over the two steps. It was 
characterised using IR, 1H and 13C NMR spectroscopy. The 1H NMR spectrum revealed a doublet 
integrating for two protons at 3.11 ppm corresponding to H-6 as well as a triplet at 2.36 ppm 
integrating for 1 proton, H-8, the two connected by long-range coupling through the triple bond. The 
13C NMR spectrum revealed the expected alkyne carbons at 71.2 and 80.0 ppm corresponding to C-8 
and C-7 respectively. All 1H and 13C NMR spectral assignments were in agreement with the published 
data.45 
3.3.2.2 Vinyl thioacetate, 15 
Having obtained the propargyl thioether, 14, attention was directed at the critical radical addition 
step. To this end, the alkyne (1.0 equiv), 14, was dissolved in toluene and the temperature increased 
to 85 °C. At this point a catalytic amount of the radical initiator ACCN (0.1 equiv) was added followed 




temperature for 3 h and then quenched with NaHCO3. 15 was isolated as a 1 : 2 mixture of E : Z 
isomers in a modest yield of 59 %. The proposed mechanism follows the classical radical mechanism 
of activation, propagation and termination as discussed in section 2.3.2. The Z-isomer of ajoene is 
reported to be the more active isomer and so it was pleasing that the reaction stereoselectivity gave 
the Z-isomer as the major product. The stereoselectivity could be explained on the basis that there is 
an equilibrium between the E- and Z- vinyl thioacetate radicals such that they interconvert (Scheme 
7). During the termination step, in which hydrogen is abstracted from thiolacetic acid, the Z-vinyl 
thioacetate reacts faster as there is less steric interference with the approaching acid, whereas in 
the E-vinyl thioacetate there is a steric factor arising with the thioacetate substituent (Scheme 7). 
Thus formation of the Z-isomer is thus preferred kinetically (for the full mechanism see section 
2.3.2). 
 
Scheme 23: Synthesis of 15  
Compound 15 was characterised using IR, HSQC, 1H and 13C NMR spectroscopy. Its IR spectrum 
showed an absorbance at 1700 cm-1 confirming the presence of a carbonyl group of a thioester. It 
was pleasing to note that the 1H NMR spectrum showed a downfield shift of the alkynyl proton in 14, 
into the vinyl region. H-3 was observed as two doublet of triplets at 6.52 (Jcis = 12.0 Hz) and 6.69 ppm 
(Jtrans = 16.0 Hz), for the two geometrical isomers, with the larger vicinal coupling constant 
corresponding to the E-isomer. Similarly, the H-4 proton was observed as an overlapping doublet of 
triplets in the region 5.70-5.89 ppm coupling to both H-5 and H-3. Interestingly, for both isomers, H-
5 was observed as a doublet of doublets coupling to both H-4 (J = 7.8 Hz) and to H-3 (J = 1.0 Hz) via 
allylic coupling. The other diagnostic peaks observed were the two singlets for the methyl of the 
acetyl at 2.39 and 2.40 ppm, corresponding to E- and Z-isomers respectively. 
The 13C NMR spectrum confirmed the presence of two isomers as all the expected 26 signals were 
observed (13 for each isomer). The most significant diagnostic peaks were the two downfield signals 
observed at 191.4 and 193.0 ppm corresponding to the acetyl carbonyl, C-2, Z- and E- respectively. 
The vinyl carbons were found at 119.7 and 119.5 ppm for C-3, 130.3 and 130.5 ppm for C-4, with C-3 
more upfield due to the shielding effect sulfur has on its neighbouring carbon atoms due to 
resonance. The methoxy signal was observed as expected at 55.4 ppm for both isomers. All proton 









Figure 27: The 1H NMR spectrum of 15 
3.3.2.3 Phenol disulfide, 16 
The next step involved deacetylation and thioalkylation of the resultant enethiolate. This was 
achieved by hydrolyzing the thioacetate with KOH in methanol at -40 °C followed by soft-S-alkylation 
of the resultant enethiolate with thiotosylate 11. The reaction was allowed to proceed overnight, at 
which point it was quenched, the product isolated via an extractive workup and the residue purified 
using column chromatography. The disulfide 16 was isolated in 79 % yield as a dark-yellow oil and as 
a 4: 5 mixture of E- : Z-isomers. Scheme 24 shows the reaction mechanism leading to the phenol 
disulfide. KOH deprotects the thiol via a base hydrolysis to give a very reactive enethiolate, thus the 
reaction temperature was kept at – 40 °C to avoid protonation and resulting Z- to E-isomerization. In 
the subsequent coupling step the temperature was lowered further to - 78 °C to retard the reactivity 
of the enethiolate. Past experience (3.1.5) had shown that this limited secondary reactions. It was 
displeasing to note that from thioacetate 15 to coupled product 16 the Z : E ratio decreased from 2 : 









Scheme 24: Synthesis of coupled product, 16. 
Although a full mechanism on this is unknown, the loss of Z-selectivity might be explained by the fact 
that in methanol (protic solvent), the enethiolate can protonate and tautomerize to the 
thioaldehyde. In the case of the Z-enethiolate the thioaldehyde can rotate about C1-C2 to minimise 
steric strain and when it deprotonates back to the enethiolate the geometry around the double 
bond has changed to the E-configuration. Scheme 25 shows the proposed mechanism for the 
inversion in stereochemistry.  
Scheme 25: Mechanistic explanation for inversion of enethiolate stereochemistry 
16 was fully characterised using HRMS, IR, HSQC, 1H and 13C NMR spectroscopy. Its IR spectrum 
showed an absorbance at 3152 cm-1 corresponding to an aromatic OH, while the 1H and 13C NMR 
spectra revealed the replication of peaks characteristic of a mixture of isomers.  
The 13C NMR spectrum revealed the C-4 downfield at 128.4 ppm (E-isomer) and 132.4 ppm (Z-
isomer), C-3 at 128.2 ppm (E-isomer) and 128.3 ppm (Z-isomer). All 8 aromatic carbon peaks were 










the synthesis of 16 was confirmed using HRMS, in which the major molecular ion was found at 
379.0849 [M+H]+ C19H23O2S3 requires 379.0860.  
Figure 28: The 1H NMR spectrum of 16 
3.3.2.4 Ajoene-analogue, 7a 
The penultimate step in the synthesis of ajoene analogue 7a was the chemoselective oxidation of 
the coupled product 16, which was achieved as before using m-CPBA in DCM at -78 °C The reaction 
mixture was stirred for 5 h, at which point there was complete disappearance of the sulfide spot and 
appearance of a new polar spot on TLC. The reaction was quenched with 1 M NaHCO3, and following 
an extractive work-up the residue was purified using column chromatography to give 7a as a light-
brown oil in a yield of 68 % and as a 1: 1 mixture of E: Z isomers. The oxidizing agent showed 
selectivity to the sulfide over the disulfide, due to the greater nucleophilicity of the sulfide as 
revealed by 1H NMR data, which showed a significant downfield shift for the H-1 and H-2 hydrogens, 
and crucially that H-2 resonated as two diastereotopic hydrogens with geminal coupling (a ddd due 
to geminal, vicinal and allylic coupling, Figures 29 and 30).  
Similarly, the 13C NMR spectrum revealed all the expected 32 carbon peaks (16 for each isomer). The 
sulfoxide had a significant deshielding effect on C-1, which was observed at 56.4 and 57.0 ppm for 
the Z- and E-isomers respectively compared to 35.6 and 34.8 ppm in Z-16 and E-16 respectively. C-2 
was also found to be significantly deshielded at 53.0 and 49.6 ppm from 29.5 and 32.9 ppm in 16 for 
the Z- and E-isomers respectively. Interestingly, the peculiar sulfoxide β-carbon position shielding 
effect noted in section 3.2.4 was also observed for compound 7a (C-3 and C-1”). All proton 













confirmed using High-Resolution Mass Spectrometry, in which the major molecular ion was found at 




Figure 29: 1H NMR spectrum of 7a and an expansion showing the H-2 splitting pattern. Note assignment of H-












Figure 30: (i) Inherent chirality of the sulfoxide, (ii) H-2 coupling pattern 
With the ajoene-analogue 7a in hand the next part in the synthesis was focused on obtaining the 
linker. For this preliminary study it was decided to use a four-chain alkyl linker, 18, containing an 
electrophilic chloroacetate functionality at one end and a protected nucleophilic hydroxyl group at 
the other (Figure 31). 
 
Figure 31: Structure of the linker, 18 
3.3.3 Synthesis of 18 
3.3.3.1 Mono-protected diol, 17 
The synthesis of the linker 18 commenced with mono-protection of 1,4-butanediol with a TBS silyl 
ether, which was achieved using the original Corey conditions of TBSCl (formerly known as TBDMSCl) 
in DMF using imidazole as base to form alcohol 17. The alcohol had to be protected to avoid 
chemoselectivity issues in the connection chemistry, and the choice of protection group was 
influenced by the fact that the subsequent steps involve base-assisted alkylation, but importantly 
the deprotection had to be achieved using mild acidic conditions under which the ajoene-analogue 
had been determined to be stable. The TBS group was a suitable candidate for this purpose because 
of its reasonable stability under basic conditions and susceptibility to deprotection under mildly 
acidic conditions.51 The product 17 was isolated as a colourless liquid in 69 % yield and was 






Scheme 26: Synthesis of mono-protected diol, 17 
Its IR spectrum revealed the expected OH stretch at 3400 cm-1, while the 1H NMR spectrum revealed 
the Si(CH3) at 0.00 ppm and the tertiary butyl methyl protons at 0.84 ppm. A diagnostic OH signal 
was observed at 3.06 ppm, while the H-3 and H-2 signals were observed upfield at 1.57 ppm and the 
H-1 and H-4 further downfield at 3.58 ppm. The 13C NMR spectrum revealed a deshielded SiCH3 at -
5.20 ppm, the quaternary SiCMe3 at 18.3 ppm, while the t-butyl methyl carbons were observed at 
26.0 ppm. The methylene C-3 and C-2 carbons were observed at 29.8 and 30.0 ppm respectively, 
while C-4 and C-1 were further downfield at 62.6 and 63.3 ppm. 
3.3.3.2 4-((tert-Butyldimethylsilyl)oxy)butyl 2-chloroethanoate, 18 
For the alkylation step to incorporate the electrophilic functionality of the linker, 17 was subjected 
to a standard SNAc reaction with chloroacetyl chloride with triethylamine as base to neutralise the 
HCl produced. In such a way 18 was isolated as a colourless oil in a good yield of 72 %, Scheme 27  
Scheme 27: Synthesis of the linker compound, 18 
18 was characterised using IR, HSQC, 1H and 13C NMR spectroscopy, with the key diagnostic signals 
being a carbonyl absorbance at 1755 cm-1, the disappearance of the hydroxyl peak in the 1H NMR 
spectrum, and a new singlet for the methylene H-1 hydrogens reasonably downfield at 4.04 ppm. 
Similarly, the 13C NMR spectrum revealed the carbonyl resonance at 167.5 ppm and a new relatively 







Figure 32: The 1H NMR spectrum of 18 
 
3.3.3.2 Alkylation of ajoene-analogue 7a 
With the ajoene 7a and the electrophilic linker 18 in hand attention was turned to the alkylation step 
to join them together (Scheme 28). Several efforts to achieve this transformation did not give the 
desired product. Alkylation using K2CO3 in acetonitrile only proceeded at temperatures above 40 °C, 
but the subsequent work-up and purification did not deliver the desired alkylated-ajoene 19. The 1H 
NMR spectrum of the isolated product showed evidence of alkylation of sulfide 7a, but it was not 
clear where the alkylation had occurred, as the aromatic ring containing the hydroxyl group was 
missing. It was postulated that the unexpected result may be due to the participation of the 
sulfoxide, as there had been a similar issue in alkylation of phenol-sulfoxide 8a. With this in mind it 









Scheme 28: Alkylation of Ajoene-analogue 7a  
3.3.3.2 Trisulfide-linker conjugate, 20 
Alkylation of sulfide 16 was achieved using the same conditions used in the attempted alkylation of 
7a using chloroacetate, 18 (2.0 equiv), with K2CO3 (2.0 equiv) in dry acetonitrile at 40 °C for 72 h, 
which gave the desired alkylated product 20 as a yellow oil and as a 7: 5 mixture of E-: Z-isomers in 
45 % yield. The poor yield was attributed to the formation of multiple by-products that were 
observed on TLC. 
 
Scheme 30: Synthesis of advanced intermediate 20 
20 was characterised using IR, HSQC, 1H and 13C NMR spectroscopy. Signals for each reactant could 
be observed with correct integration in the product. Notably, the silyl grouping compared favourably 
against the aromatic and vinyl integrations. Otherwise, the expected signals were observed as in the 
precursors. The 13C NMR spectrum revealed all of the expected 46 peaks (23 for each isomer), while 
a carbonyl resonance was observed at 170.0 ppm for the ester (C-6’), The 1H NMR spectrum with 











Figure 33: 1H NMR spectrum of trisulfide-linker conjugate 20 
The full synthesis to the ajoene-fludarabine conjugate was not achieved due to time constraints. 
Small-scale preliminary studies seemed to show that the sulfide 20 could be chemoselectively 
oxidised to the sulfoxide 19 using m-CPBA (this was based on monitoring TLC reaction progress, 
where a similar reaction profile was observed to that for the oxidation to 7a, (page 67), while silyl 
deprotection studies on 19 and 20 with catalytic amounts of acetyl chloride in methanol showed 
that it was much more convenient to work with the sulfide 20, as the sulfoxide 19 (used without 
purification from reaction above) gave unstable by-products upon deprotection. 
Regarding preparation of the commercially available (and very polar) fludarabine phosphate group 
for coupling, literature reports had suggested that a sequence of hydroxyl protection on fludarabine  
followed by activation of the hydroxyl groups of the phosphoric acid moiety using 2,4,6-TIPSCl 
(triisopropylphenylsulfonyl chloride), both steps carried out in situ, would furnish a derivative 
appropriate for coupling with the ajoene-alcohol (from deprotection).48a  
As part of a preliminary model study on this, protection of the fludarabine hydroxyl groups of 
fludarabine phosphate with TBSCl (2.5 equiv) and imidazole was attempted, Scheme 31.  










Scheme 31: TBS protection of fludarabine 
Following a difficult chromatographic isolation using a very polar mobile phase of 4:20:76 (NEt3: 
MeOH: DCM) product 21 was obtained. Its 1H NMR spectrum is shown in Figure 34 together with 
assignments. Although there are impurities in the spectrum, the structure as shown in Figure 34 for 
21 was assigned. When excess TBSCl was used the protection of both 2’ and 3’ hydroxyl groups was 
not observed, and this is most likely due to the steric strain that would result in such a case. Chhikara 
et al reported that silylation of cytarabine with TBSCl occurs more readily on the 3’ hydroxyl group 
in.48b Thus it is suspected that this might be the case in fludarabine with silylation occurring on the 
less hindered face of the arabinose sugar as depicted in Scheme 31. Owing to time constraints this is 










Figure 34: 1H NMR of 21  
3.4 Conclusions on the Synthesis Studies 
Analogues of ajoene lacking the double bond (dihydroajoene series) were successfully synthesized 
for the purposes of a Structure-Activity Relationship (SAR) study, in which analogues 8a, and 13a-d 
were evaluated for their biological activity against the oesophageal cancer cell line WHCO1. The 
Ester-Sulfoxide, 8c, was not evaluated as it was deemed not to be of the required purity (>95 %) by 
LCMS. It was also displeasing that the two analogues 8b and 8d could not be obtained in good 
enough purity for the SAR study.  
A preliminary study towards an ajoene-fludarabine conjugate was explored. An advanced 
intermediate 20 was successfully synthesized, as well as preliminary studies carried out on 
preparation of the fludarabine partner for coupling, but owing to time constraints the full synthesis 
of an ajoene-fludarabine conjugate was not achieved  








Chapter 4: Biological Evaluation of Ajoene Analogues 
 
4.1 Introduction  
 
In previous work, several ajoene analogues were evaluated in an SAR study and a lead compound 6a, 
was identified.45  6a was found to exhibit the strongest activity against WHCO1 cell proliferation with 
an IC50 of 2.1 µM.
45 In a subsequent study several analogues (7a-d) were synthesized to improve the 
aqueous solubility of 6a and these analogues were found to retain good activity against the same 
cancer cell-line, see Figure 34 below for structures.47 Here, several aqueous enhancing groups were 
incorporated on the phenol end of the molecule to be  amide, acetate and ester functional groups 
(Fig 34) that increased water solubility via hydrogen-bonding.  Indeed the aqueous solubilities of 7a-
d were all improved compared to that of the lead 6a as shown in a turbidmetric study.47 
In two in vivo experiments the compounds 6a and 7d were found to be ineffective at reducing 
tumour cell growth.45, 47 The failure of the lead 6a was possibly attributed to its insolubility in the 
delivery intralipid vehicle.  In the case of 7d however, the analogue was much more soluble in the 
intralipid vehicle, hence it was felt that its failure could not be attributed to solubility issues alone. 
Thus a second consideration was that the compounds were likely to be metabolically unstable which 
may prevent their delivery to the tumour site.47 
The metabolic stability of 6a was therefore evaluated in vitro in mouse blood where a degree of 
stability was noted in plasma but 6a was found to be unstable in both the whole blood and red blood 
cell fractions as demonstrated by an HPLC blood aliquot monitoring experiment (see Figure 11).47 
This result suggested that the compound was interacting with red blood cells causing rapid 
degradation of the compound. We went on to speculate that this instability may be structurally 





Fig 34: Structures of the lead compound 6a, ajoenes 7a-d and the dihydroajoenes 13a-d and 8a. 
To test this hypothesis, a new set of compounds (dihydroajoenes) mirroring the analogues 7a-d but 
lacking the vinyl disulfide were designed to possibly circumvent the metabolic stability issues of 6a. 
Owing to synthetic challenges the whole library of analogues mirroring 7a-d were not obtained. The 
dihydroajoene analogues synthesized have been discussed previously in Chapter 3 and shown here 
in Figure 34.  
Thus, the biological evaluation set about to establish if in vitro WHCO1 anti-proliferation activity 
could be retained in analogues 8a, 13a-d lacking the vinylic-disulfide bond, and finally whether these 
analogues were stable in blood. 
4.2 Determination of the IC50 of Ajoene Analogues 
 
4.2.1 Measurement of Anti-Cancer Activity 
The ajoene analogues synthesized were tested for their ability to inhibit cell proliferation of WHCO1 
cancer cells using an MTT assay. The oesophageal cancer cell-line WHCO1 was derived from a biopsy 
of a primary oesophageal squamous cell carcinoma of South-African origin.45 The MTT assay is based 
on the ability of metabolically active cells to cleave [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetazolium bromide] salt (MTT) to formazan crystals (Figure 35).  
Living cells have active mitochondrial reductase which can metabolise MTT to formazan (Figure 35) 
which does not occur in metabolically inactive cells. The assay relies on colorimetric evaluation to 
assess cell viability. The tetrazolium salt (MTT) is yellow coloured and water soluble whilst formazan 




solubilizing reagent and quantitated colorimetrically using a scanning multiwall spectrophotometer, 
with the absorbance measured at 595 nm. The amount of formazan formed is proportional to the 
number of viable cells. 
 
Figure 35: Conversion of MTT by the mitochondrial reductase 
The absorbance results from the assay were analysed using Graphpad prism 6 software, using the 
sigmoidal dose-response (variable slope) to fit the curve and determine the IC50 value. The IC50 is 
defined as the concentration of compound required to inhibit 50 % of cell proliferation. 
4.2.2 MTT Assay 
WHCO1 cells were plated in 96-well plates and allowed to recover and settle overnight. The 
following day they were treated with drug dissolved in DMSO and diluted in media such that the 
final concentrations were 0-150 µM drug and 0.1 % DMSO. The duration of drug treatment was 48 h 
and at that point MTT solution was added. After 4 h incubation with the MTT reagent, solubilisation 
reagent was added to each well and the cells were incubated overnight. The following day, the 
absorbance was measured at 595 nm. The spectrophotometric data was analysed using Graphpad 
prism 6, fitted to a sigmoidal dose-response curve with a non-variable slope from which the IC50 was 
determined. Figure 36 shows representative sigmoidal dose-response graphs for each of the 
compounds. Each compound IC50 is calculated as the mean of at least three independent 
determinations (± standard deviation), the results are summarised, together with some previous 




Figure 36: Representative sigmoidal dose-dependent curves of absorbance at 595 nm vs 
concentration for the determination of IC50s.  
 4.2.3 MTT Assay Results and SAR Analysis 
All dihydroajoene analogues synthesized with the exception of the ester analogue 13c, were found 
to be active in vitro with an anti-proliferative IC50 in the range 1-40 µM as shown in Table 7. The 
phenol-sulfoxide 8a was found to be the most active with an IC50 of 4.1 µM, which is comparable to 
that of the advanced lead compound 6a of 2.1 µM against the same cell-line. The dihydroajoenes in 
which both the vinyl disulfide and sulfoxide were removed, namely phenol, 13a (39 µM), acetate 13b 
(39 µM) and amide 13d (29 µM), all displayed roughly 10-fold reduced activity compared to the 
analogous derivatives containing a sulfoxide and double bond 7a (1.9 µM), 7b (3.6 µM), 7c (1.7 µM) 
and 7d (7.7 µM) which were synthesized and evaluated in a prior study. It is not clear why the 
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dihydroajoene ester 13c is inactive but there is likely to be another, as yet to be identified, factor 
involved for this compound. 
Table 7: A comprehensive table of anti-proliferative IC50’s (WHCO1 cells) for previously synthesized ajoene 
analogues together with the analogues synthesized in the current study.  
Dihydroajoene-analogues 
 




























16 ± 3.7 47 
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1.7  0.9 47 
 
                              13d 
29  ± 16 
                                7d 
7.7  1.747 
 
 
Interestingly, diallyl disulfide was found to be inactive against WHCO1 cancer cell proliferation when 
tested up to 200 µM implying that the presence of the disulfide functional group alone is not 




Previously an 8-fold reduction in activity was found when the vinyl group of compound 6a was 
removed in 6e. For the phenol series (7a, 8a and 13a) removal of the vinyl group in 7a still resulted 
in decreased activity however to a lesser extent (only 2-fold) compared to 6a, with the resulting 
derivative 8a still exhibiting good activity of 4 µM.  
Certain conclusions on the SAR can be drawn:  
 Most importantly, activity can be retained in the absence of the vinyl group as all 
dihydroajoene compounds, except for the ester 13c, were found to exhibit good anti-
proliferation activity. 
 Removal of the vinyl group results in a reduced activity: a 2-fold reduction of activity in the 
phenol series 7a to 8a; and an 8-fold in the bis-paramethoxy series 6a to 6e. 
 When the vinyl group is removed, the sulfoxide is necessary for retention of good activity. 
When the both the double bond and sulfoxide were removed from 7a to analogue 13a the 
activity dropped about 20-fold, while removal of only the vinyl group as in 8a retains good 
activity. 
The previous SAR study already established that the disulfide bond is the pharmacophore and that 
the vinylic bond serves to activate the pharmacophore.45 The results presented show that the 
relative activity of the ajoene analogues is dependent on the electrophilicity of the disulfide bond. 
With the vinyl bond and sulfoxide amplifying this electrophilicity via a resonance and an inductive 
electron withdrawing effect respectively (Scheme 32). This observation suggests that the mode of 
action of these compounds is via a disulfide exchange mechanism, in which a mixed disulfide is 
formed between ajoene analogues and an accessible thiol on a cysteine residue. This is in support of 
work reported by Krauth-Siegel et al who showed that ajoene forms a mixed disulfide with Cys-58 of 
glutathione reductase.40  
 
Scheme 32: Induced electrophilicity on the disulfide bond through a) resonance stabilisation of the leaving 




Having ascertained that analogues lacking the vinyl group and with increased water solubility 
retained anti-proliferative activity, the focus was turned to the metabolic stability of these analogues 
in mouse blood. 
4.5 Blood Stability Study 
 
A preclinical matrix stability study on ajoene analogues was performed on our behalf, at the Division 
of Pharmacology at the University of Cape Town. Analogues were evaluated for their in vitro stability 
in both mouse plasma and in the red blood cell fraction of mouse blood. Only the following 
compounds were evaluated in this study: 6a, 7a-7d and 13b-13d. 
Stock solutions of the compounds were prepared in DMSO at a concentration of 20 mg/mL. The 
stock solutions were diluted 10-fold to 2 mg/mL and then a further 10-fold to yield 200 µg/mL 
solutions. Blood was collected from 10 mice and stored at room temperature in K2EDTA coated 
tubes. Two matrixes were prepared namely plasma and red blood cell matrixes. The experiment 
commenced with each matrix being spiked with analogue compound to give a final concentration of 
20 µg/mL and then incubated at 37 ° C. Aliquots of 10 µL were removed at the following times:  0 
(baseline), 20, 60 and 120 minutes and analysed by High Performance Liquid Chromatography 
coupled to Mass Spectroscopy to detect and quantify the parent molecular ion. The results are 
shown in the charts below, where analyte peaks were calculated as a percentage of the baseline 
value measured at 0 minutes.  
The compounds (6a, 7a-d and 13b-d) were found to have vastly different stabilities in the plasma 
matrix, with the dihydro derivatives considerably more stable compared to their ajoene 
counterparts, apart from bis-pmb 6a. In the dihydroajoene series the ester 13c was the least stable 
of the three derivatives tested (Figure 35), although as this derivative was inactive in vitro it was of 
no consequence that it was found to be relatively unstable in the plasma fraction. However, it was 
extremely pleasing that the two dihydro analogues 13b and 13d (active in vitro) were relatively 





Figure 35 Stability of ajoene analogues in blood plasma. 
 
 
Figure 36: Stability of ajoene analogues in red blood cells 
With the stability of the compounds in plasma setting the scene, it was informative to note that their 
stability in red blood followed a similar trend, with the dihydro compounds much more stable than 
the ajoene derivatives. As with the plasma results ester 13c proved to be the least stable. Overall, 
amide 13d emerged as having the best characteristics in both systems. The results support the 































































blood. The relative stability, in RBCs, of the dihydroajoene series compounds 13b and 13d was 
pleasing as this was an improvement on the stability of the lead compound 6a. In light of this 
improved metabolic stability of 13b and 13d, it may be interesting to test whether these compounds 
are stable enough to reach the tumour site and deliver their apoptosis-inducing potential in an in 
vivo experiment. 
4.6 Conclusion  
 
Most of the analogues synthesized in this project (dihydroajoene series) had comparable or superior 
activity to that of the parent compound ajoene at inhibiting proliferation of WHCO1 cancer cells. The 
phenol-sulfoxide 8a was the most promising analogue with an IC50 of 4.1 µM, which was only 2-fold 
less active than the lead bis-pmb, 6a.  
Dihydroajoene analogues 13b and 13d were significantly much more stable in the red blood cell 
fraction of blood than the vinyl disulfide analogues 7a-7d. This result agrees with our initial 
hypothesis that the double bond of the vinyl disulfide may be the source of instability of ajoene 
analogues in blood. Though compound 8a was not evaluated for metabolic stability, it is predicted 
that this compound would be much more stable than lead 6a in RBCs owing to the absence of the 
vinyl disulfide. The sulfoxide and phenolic OH group should also enhance 8a’s water solubility. 
Coupled with its good activity the results make 8a a suitable candidate for an in vivo animal 
evaluation.  
This study aimed to address two questions:  
Is the double bond essential for activity? and 
Does its removal aid in increasing metabolic stability 
In conclusion, this study has found that: 1) the double bond is not essential for retention of activity 






Chapter 5: Conclusion 
 
In conclusion, new analogues of ajoene were synthesized. The developed synthetic route is 
divergent and spans over 7 steps with the focus on obtaining a phenol derivative, on which various 
water enhancing groups can be installed.  The analogues retained good anti-proliferation activity 
against WHCO1 cancer cell line, with the phenol-sulfoxide 8a derivative being the most active. From 
an SAR study it was established that the vinyl double bond is not essential for retention of activity 
but the sulfoxide was important for enhancing the activity in the absence of the vinyl bond. It was 
exciting to note that the dihydroajoene analogues acetate, 13b, and amide, 13d, were much more 
stable in blood than ajoene analogues containing a double bond.  Overall, the results give hope that 
a successful in vivo ajoene analogue candidate will be found.  
A preliminary study towards the synthesis of an ajoene-fludarabine conjugate was initiated and an 
advanced intermediate of ajoene coupled to a linker, 20, was obtained. Preliminary preparation of a 
fludarabine coupling counterpart was also explored (not reported). With further work it is possible 










Chapter 6: Experimental 
 
6.1 General:  
All reaction solvents were freshly distilled under a nitrogen atmosphere. DCM was distilled over 
phosphorus pentoxide, acetonitrile was distilled over calcium hydride and THF was distilled over 
sodium wire and benzophenone. Anhydrous methanol was degassed using nitrogen gas. Reagents 
were obtained from commercial sources (Sigma–Aldrich, Fluka, Merck).  
All reaction flasks were dried in the oven (50 °C) and all reactions were carried out using magnetic 
stirrers. Unless otherwise stated all reactions were carried under a nitrogen atmosphere. Low- 
temperature reactions were carried out using acetone in liquid nitrogen (-94 °C), ice and NaCl (-20 
°C), ice and calcium chloride (- 10 °C) or an ice bath (0 °C).  
Thin layer chromatography (TLC) was used to monitor reactions using aluminium-backed Merck 
silica-gel 60 F254 plates. Compounds on TLC plates were observed using ultraviolet light and stained 
with either: 2.5 % solution of anisaldehyde in a mixture of sulphuric acid and ethanol (1:10 v/v) or 
iodine vapour and then heated. Column chromatography was carried out using silica-gel 60 mesh 
(Merck). 
Nuclear Magnetic Resonance (NMR) spectra were recorded on either a Bruker XR400 MHz 
spectrometer (at 399.95 MHz for H1, 100.58 MHz for 13C), or a Varian Mercury XR400 MHz 
spectrometer (at 399.95 MHz for H1 and at 100.58 MHz for 13C), or a Varian Mercury XR300 MHz 
spectrometer (at 300.08 MHz for H1 and at 75.46 MHz for 13C). Chemical shifts are reported in ppm 
and J values are reported in Hz, with internal references for CHCl3 in the CDCl3 taken as 7.26 ppm for 
1H and 77.16 ppm for 13C NMR spectra. High Resolution Mass spectrometry was performed on a 
Water API Q-TOF Ultima machine at The University of Stellenbosch Central Analytical Facilities. 
Infrared spectra were obtained on a Perkin-Elmer Paragon 1000 FT-IR spectrometer. Melting point 









6.2 Synthesis Experimental 
4-(2-Hydroxyethyl)phenol (1)49 
 
Methyl 4-hydroxyyphenylacetate (3.00 g, 18.05 mmol) was added slowly to a stirring suspension of 
LiAlH4 (1.39 g, 36.0 mmol) in THF (60 mL) at -78 °C. The reaction proceeded under N2 for 2 h at which 
point the reaction mixture was quenched with 1 M HCl (to pH 4). The resulting suspension was 
filtered through Celite washing with warm EtOAc (40 mL). The aqueous layer was extracted using 
EtOAc (3 x 40 mL). The combined organic extracts were washed with water (3 x 20 mL), then brine 
(20 mL) and dried over MgSO4. Solvent was removed under reduced pressure and the crude product 
purified by flash chromatography using petroleum ether/ EtOAc mixtures. The product (1) was 
recrystallised from ethyl acetate and hexane and isolated as a white powder (2.00 g, 82 %). 
Rf = 0.2 (Hexane / EtOAc = 80 / 20); Mp: 86-88 °C, lit39 Mp: 87-89 °C; IR νmax/ cm-1 (KBr): 3391 (ROH), 
3152 (ArOH); 1H NMR (400 MHz,d6-acetone) δ 2.71 (2H, t, J = 7.1 Hz, H-5), 3.53 (1H, brs, OH), 3.69 
(2H, t, J = 7.1 Hz, H-6), 6.74 (2H, d, J = 8.4 Hz, H-2), 7.05 (2H, d, J = 8.4 Hz, H-3), 8.00 (1H, brs, PhOH); 




Iodine (0.548 g, 2.16 mmol), triphenylphosphine (0.566 g, 2.16 mmol) and imidazole (0.147 g, 2.16 
mmol) were dissolved in THF (7 mL) at room temperature. Alcohol 1 (0.251 g, 1.82 mmol) in THF (2 
mL) was added to the reaction vessel and the reaction was allowed to proceed for 3 h under N2 at 
room temperature. Thereafter the reaction was quenched using a concentrated solution of Na2SO3 
(10 mL) and the mixture stirred for 10 minutes. The aqueous layer was extracted using EtOAc (3 x 15 
mL), the combined organic extracts were washed with a concentrated solution of Na2SO3 (15 mL),  
1 M HCl (10 mL) and NaHCO3 (10 mL) and dried over MgSO4. The solvent was removed under 
reduced pressure and the residue purified by column chromatography using a mixture of EtOAc and 




Rf = 0.6 (Hexane / EtOAc = 80 / 20); Mp: 112-113 °C, lit 40 Mp: 111-112°C; IR νmax/ cm-1 (CHCl3): 3152 
(ArOH), 500 (C-I); 1H NMR (400 MHz, CDCl3): δ 3.10 (2H, t, J = 8.0 Hz, H-5), 3.31 (2H, t, J = 8.0 Hz, H-6), 
4.87 (1H, s, PhOH), 6.78 (2H, m, H-2), 7.06 (2H, m, H-3); 13C NMR (100 MHz, CDCl3)  
δ 6.2 (C-6), 39.5 (C-5), 115.5 (C-2), 129.5 (C-3), 133.1 (C-4), 154.4 (C-1). 
S-4-Hydroxyphenethyl 4-methylbenzenesulfonothioate (3) 
 
4-(2-Iodoethyl)phenol (2) (0.862 g, 3.48 mmol) was dissolved in anhydrous DMF (10 mL) and then 
potassium thiotosylate (2.36 g, 10.44 mmol) was added to the solution. The reaction mixture was 
stirred at room temperature under N2 for two hours, at which point there was complete conversion 
of the substrate based on the appearance of a new polar spot on TLC. The reaction mixture was 
suspended in H2O (10 mL) and then diluted with EtOAc (15 mL). The aqueous layer was extracted 
using EtOAc (3 x 15 mL), the combined organic fractions were then washed with H2O (5 x 10 mL) and 
dried over MgSO4. The solvent was removed under reduced pressure and the residue was purified by 
column chromatography using mixtures of hexane and EtOAc to yield (3) as a brown oil (0.976 g, 91 
%).  
Rf = 0.5 (Hexane / EtOAc = 80 / 20); IR vmax/cm
-1
 (CHCl3): 3152 (ArOH), 1228 (O=S=O); HRMS (ES) m/z: 
309.0615 [M+ H] +, C15H17O3S2 requires 309.0619; 
1H NMR (400 MHz, CDCl3) 2.45 (3H, s, H-1), 2.83 
(2H, t, J = 7.6 Hz, H-6), 3.18 (2H, t, J = 7.6 Hz, H-7), 3.38 (1H, s, OH), 6.74 (2H, d, J = 8.5 Hz, H-10), 6.95 
(2H, d, J = 8.5 Hz, H-9), 7.34 ( 2H, d, J = 8.5 Hz, H-3), 7.81 (2H, d, J = 8.5 Hz, H-4); 13C NMR (101 MHz, 
CDCl3)  21.8 (C-1), 34.4 (C-6), 37.6 (C-7), 115.7 (C-10), 127.2 (C-9), 129.9 (C-4), 130.0 (C-3), 131.0 (C-
8), 142.3 (C-5), 144.9 (C-2), 154.7 (C-11). 
3-((4-Methoxybenzyl)thio)propane-1-thiol (4) 
 
Propane-1,3-dithiol (486 mg, 4.50 mmol) was dissolved in degassed anhydrous methanol (15 mL) in a 
three-necked flask. Potassium hydroxide pellets (328 mg, 5.80 mmol) were added to the reaction 




added to the reaction vessel dropwise and the reaction was left to proceed for 2 hours at 0 °C. 
Thereafter, the reaction mixture was quenched with 1 M HCl (10 mL). The aqueous layer was 
extracted using EtOAc (3 x 30 mL) and the combined organic extracts were washed with water (3 x 
30 mL) and brine (10 mL) and then dried over MgSO4. The solvent was removed under reduced 
pressure, and the crude mixture purified by column chromatography using EtOAc and Hexane (3 : 
97) to yield (4) as an odoriferous lime-green-coloured oil (661 mg, 71 %).  
Rf = 0.85 (Hexane / EtOAc = 90 / 10) 
1H NMR (400 MHz, CDCl3): δ 1.31 (1H, t, J = 8.0 Hz, S-H), 1.84 
(2H, quin, J = 7.2 Hz, H-2) , 2.52 (2H, t, J = 7.2 Hz, H-3), 2.58 (2H, q, J = 7.6 Hz, H-1), 3.66 (2H, s, H-4), 
3.80 (3H, s, OMe), 6.84 (2H, d, J = 8.8 Hz, H-7 ), 7.22 (2H, d, J = 8.8 Hz, H-6 ); 13C NMR (100 MHz, 
CDCl3): δ 23.6 (C-1), 29.7 (C-3), 33.2 (C-2), 35.8 (C-4), 55.4 (OMe), 114.0 (C-7), 130.0 (C-6), 130.4 (C-
5), 158.8 (C-8).  
1-(p-Methoxyphenyl)-9-(4-hydroxyphenyl)-2,6,7-trithianonane  (5) 
 
 Thiol (4) (250 mg, 1.1 mmol) dissolved in triethylamine (0.31 mL, 2.25 mmol) was added dropwise to 
a solution of sulfonylthioate (3) (0.704 g, 2.2 mmol) in anhydrous methanol (10 mL) at -78°C. The 
reaction was allowed to proceed for 30 mins, after which there was full conversion of the thiol 
substrate according to TLC, at which point the methanol and excess triethylamine were removed 
under reduced pressure. The crude product was purified directly by column chromatography using 
EtOAc and Hexane (5-20% EtOAc) to afford (5) as a yellow oil (368 mg, 88%).  
Rf = 0.4 (Hexane / EtOAc = 70 / 30); IR vmax/cm-1 (CH2Cl2): 3054 (ArOH), 705 (C-S); m/z (ES) : 379.0860 
[M-H]+ C19H23O2S3 requires 379.0866; 
1H NMR (400 MHz, CDCl3) δ 1.93 (2H, quin, J = 7.2 Hz, H-3), 2.51 
(2H, t, J = 7.2 Hz, H-2), 2.73 (2H, t, J = 7.2 Hz, H-4), 2.89 (4H, brs, H-5, H-6), 3.67 (2H, s, H-1), 3.79 (3H, 
s, OMe), 4.77 (1H, s, O-H), 6.75 (2H, d, J = 8.8 Hz, H-3’), 6.84 (2H, d, J = 8.8 Hz, H-3”), 7.05 (2H, d, J =  
8.8 Hz, H-2’), 7.22 (2H, d, J = 8.8 Hz, H-2”); 13C NMR (100 MHz, CDCl3): δ 28.6 (C-3), 29.9 (C-2) 35.0 (C-
5), 35.9 (C-1), 37.7 (C-4), 40.7 (C-6), 55.5 (OMe), 114.1 (C-3”), 115.5 (C-3’), 129.9 (C-2’), 130.0 (C-2’’), 








To a solution of phenol (5) (0.150 g, 0.395 mmol) and triethylamine (0.08 mL, 0.56 mmol) in DCM (5 
mL) at – 78 °C, was added acetyl chloride (0.043 ml, 0.56 mmol) drop-wise. The reaction was stirred 
under N2 for 1 h at which point 1 M HCl (5 mL) was used to quench the reaction. The aqueous layer 
was extracted with DCM (3 x 10 mL), the combined extracts were washed with H2O (3 x 10 mL) and 
dried over MgSO4. The solvent was removed under reduced pressure and the residue purified by 
column chromatography using mixtures of EtOAc and hexane to give the desired product (6) as a 
yellow oil (0.110 g, 64 %). 
Rf = 0.5 (Hexane / EtOAc = 70 / 30); IR vmax/cm-1 (CH2Cl2): 1750 (C=O), 705 (C-S); m/z (ES): 445.0933 
[M + Na]+, C21H26NaO3S3 requires 445.0942; 
1H NMR (400 MHz, CDCl3): δ 1.96 (2H, quin, J = 7.2 Hz H-
3), 2.30 (3H, s, H-6’), 2.53 (2H, t, J = 7.2 Hz, H-2), 2.76 (2H, t, J = 7.2 Hz, H-4), 2.91 (2H, m, H-5), 3.00 
(2H, m, H-6), 3.71 (2H, s, H-1), 3.82 (3H, s, OMe), 6.87 (2H, d, J = 8.8 Hz, H-3”), 7.04 (2H, d, J = 8.8 Hz, 
H-2’), 7.25 (4H, m, H-2”and H-3’); 13C NMR (100 MHz, CDCl3): δ 21.1 (C-6’), 28.5 (C-3), 29.8 (C-2), 35.1 
(C-5), 35.7 (C-1), 37.5 (C-4), 40.0 (C-6), 55.3 (OMe), 114.0 (C-3”), 121.6 (C-2’), 129.6 (C-2”), 130.0 (C-
3’), 130.3 (C-1”), 137.5 (C-1’), 149.4 (C-4’), 158.9 (C-4”), 169.5 (C-5’).  
1-(p-Methoxycarbonylmethyloxyphenyl)-9-(p-methoxyphenyl)-2,6,7-trithianonane (7) 
 
Potassium carbonate (35 mg, 0.26 mmol) was added to a stirring solution of phenol (5) (65 mg, 0.17 
mmol) in dry acetonitrile (2 mL). After stirring the reaction for 5 min at room temperature, methyl 2-
bromoacetate (40 mg, 0.26 mmol) was added, the reaction temperature was raised to  
45 °C and the contents stirred overnight under N2. The reaction was diluted with H2O (15 mL), and 
the aqueous layer extracted using EtOAc (3 x 10 mL). The combined organic extracts were washed 




removed under reduced pressure and the residue purified by column chromatography using 
mixtures of EtOAc and hexane. The product (7) was isolated as a dark-yellow oil (60 mg, 78%). 
Rf = 0.15 (Hexane / EtOAc = 90 / 10); IR vmax/cm-1 (CH2Cl2): 1750 (C=O); HRMS m/z (ES): 475.1047 [M+ 
Na]+, C22H28NaO4S3 requires 475.1047; 
1H NMR (400 MHz, CDCl3): δ 1.94 (2H, quin, J = 7.1 Hz, H-3), 
2.50 (2H, t, J = 7.0 Hz, H-2), 2.73 (2H, t, J = 7.0 Hz, H-4), 2.89 (2H, m, H-5), 2.90 (2H, m, H-6),  
3.67 (2H, s, H-1), 3.79 (3H, s, H-7’), 3.80 (3H, s, OMe), 4.61 (2H, s, H-5’), 6.83 (4H, d, J = 7.2 Hz, H-3’ 
and H-3”), 7.11 (2H, d, J = 8.4 Hz, H-2’), 7.20 (2H, d, J = 8.4 Hz, H-2”); 13C NMR (100 MHz, CDCl3): δ 
28.6 (C-3), 29.8 (C-2), 35.0 (C-5), 35.8 (C-1), 37.7 (C-4), 40.4 (C-6), 52.5 (C-7’), 55.4 (O-Me), 65.7 (C-
5’), 114.1 (C-3”), 114.9 (C-3’), 129.9 (C-2”), 130.0 (C-2’), 130.4 (C-1”), 133.5 (C-1’), 156.7 (C-4” and C-
4’), 169.7 (C-6’).  
9-(p-Acetamidophenyl)-1-(p-methoxyphenyl)-2,6,7-trithianonane (8) 
 
Phenol (5) (0.150 g, 0.39 mmol) dissolved in dry acetonitrile (1 mL) was added to a mixture of  
potassium carbonate (0.082 g, 0.59 mmol) in dry acetonitrile (2 mL), the mixture was stirred for 5 
mins before addition of chloroacetamide (55 mg, 0.59 mmol). The temperature was then raised to 
45 °C and the reaction mixture stirred under N2 for 12 h. The reaction was diluted with H2O (10 mL) 
and the aqueous layer extracted using EtOAc (3 x 30 mL). The combined organic extracts were 
washed with H2O (3 x 30 mL) and dried over MgSO4.The solvent was removed under reduced 
pressure and the residue purified by column chromatography using mixtures of methanol and DCM 
to yield the title compound (8) as a white powder (0.133 g, 77 %).  
Rf = 0.2 (Hexane / EtOAc = 50 / 50); Mp: 83-85 °C; HRMS (ES) m/z: 460.1046 [M+ Na]+ C21H27NNaO3S3 
requires 460.1051; 1H NMR (400 MHz, CDCl3): δ 1.93 (2H, quin, J = 7.0 Hz, H-3), 2.51 (2H, t, J = 7.2 Hz, 
H-2), 2.74 (2H, t, J = 7.2 Hz, H-4), 2.81 (4H, m, H-5 and H-6) 3.67 (2H, s, H-1), 3.79 (3H, s, O-Me), 4,47 
(2H, s, H-5’), 6.00 (1H, s, N-H), 6.54 (1H, s, N-H), 6.85 ( 4H, m, H-3’ and H-3”), 7.14 (2H, d, J = 8.8 Hz, 
H-2’), 7.21 (2H, d, J = 8.8 Hz, H-2”); 13C NMR (100 MHz, CDCl3): δ 28.6 (C-3), 29.9 (C-2), 34.8 (C-5), 
35.8 (C-1), 37.6 (C-4), 40.4 (C-6), 55.4 (OMe), 67.5 (C-5’), 114.1 (C-3”), 114.9 (C-3’), 130.0 (C-2’ and C-





9-(p-Hydroxyphenyl)-1-(p-methoxyphenyl) -2, 6, 7-trithianonane-2-oxide (9) 
 
Phenol (5) (129 mg, 0.34 mmol) was dissolved in DCM (2 mL), the reaction temperature was lowered 
to –78 °C and then m-CPBA (91.3 mg, 77 % in H2O, 0.53 mmol) was added slowly. After 1 hour the 
reaction was quenched with saturated Na2C03 (6 mL). The aqueous layer was extracted with DCM (3 
x 10 mL), the combined organic fractions were washed with H2O (3 x 10 mL). The combined organic 
fractions were dried over MgSO4, the solvent removed under reduced pressure and the residue 
purified by column chromatography using mixtures of DCM / methanol to yield (9) (100 mg, 72%) as 
a colourless oil.  
Rf = 0.2 (DCM / Methanol = 95 / 5); HRMS (ES) m/z: 397.066 [M+ H]
+ C19H24NO3S3 requires 397.066; 
IR vmax/cm-1 (CH2Cl2): 3054 (ArOH), 1265 (S=O), 705 (C-S); 1H NMR (400 MHz, CDCl3): δ 2.13 (2H, m, H-
3), 2.69 (4H, m, H-2 and H-4), 2.88 (4H, brs, H-5 and H-6), 3.80 (3H, s, OMe), 3.95 (1H, d, J = 12.0 Hz, 
H-1a), 4.00 (1H, d, J = 12.0 Hz, H-1b), 6.76 (2H, d, J = 8.0 Hz, H-3’),  6.89 ( 2H, d, J = 8.0 Hz, H-3”), 7.01 
( 2H, d, J = 8.0 Hz, H-2’), 7.20 ( 2H, d, J = 8.0 Hz, H-2”); 13C NMR (100 MHz, CDCl3): δ 22.3 (C-3), 34.9 
(C-5), 37.3 (C-4), 41.1 (C-6), 48.9 (C-2), 55.5 (OMe), 57.8 (C-1), 114.7 (C-3”), 115.8 (C-3’), 121.4 (C-1”), 
129.9 (C-2’), 131.4 (C-2”), 131.7 (C-1’), 154.9 (C-4’), 160.0 (C-4”). 
9-(p-Methoxycarbonylmethyloxyphenyl)-1-(p-methoxyphenyl)-2, 6, 7-trithianonane-2-oxide (10) 
 
Sulfoxide (9) (66 mg, 0.17 mmol) and potassium carbonate were stirred in acetonitrile (5 mL) and 
after stirring for 5 minutes methyl bromoacetate (39.1 mg, 0.26 mmol) was added, the reaction 
temperature was raised to 45 °C and the reaction was stirred under N2 for 1 h. The reaction mixture 
was quenched with 1 M HCl (10 mL) and the aqueous layer extracted using EtOAc (3 x 10 mL) the 




were dried over MgSO4, the solvent removed under reduced pressure and the residue purified by 
column chromatography using mixtures of DCM and methanol. The product (10) was isolated as a 
yellow oil (60 mg, 77 %).  
Rf = 0.2 (DCM / Methanol = 95 / 5), LC-MS m/z: 491.0. [M+ Na]
+, C22H28NaO5S3 requires 491.0997; IR 
vmax/cm
-1
 (CH2Cl2): 1750 (C=O), 1265 (S=O), 705 (C-S); 
1H NMR (400 MHz, CDCl3): δ 2.10 (2H, m, H-3), 
2.58-2.78 (4H, m, H-2 and H-4), 2.83 (4H, m, H-5 and H-6), 3.55 (6H, s, OMe and H-7’)  3.84 (1H, d, J = 
12.0 Hz, H-1a), 3.90 (1H, J = 12.0 Hz, H-1b), 4.55 ( 2H, s, H-5’), 6.76 (2H, d, J = 8.0 Hz, H-3’), 6.82 (2H, 
d, J = 8.0 Hz, H-3”), 7.10 ( 2H, d, J = 8.0 Hz, H-2’), 7.20 (2H, d, J = 8.0 Hz, H-2”),; 13C NMR (100 MHz, 
CDCl3): δ 22.3 (C-3), 34.9 (C-5), 37.4 (C-4), 40.4 (C-6), 49.0 (C-2), 52.4 (C-7’), 55.5 (OMe), 57.9 (C-1), 
65.6 (C-5’), 114.7 (C-3”), 114.9 (C-3’), 121.6 (C-1”), 129.9 (C-2’), 131.4 (C-2”), 134.0 (C-1’), 156.7 (C-
4’), 160.0 (C-4”), 169.6 (C-6’).  
S-(3-(p-Methoxyphenylmethylthio)propyl) ethanethioate (11) 
 
Potassium carbonate (0.726 g, 5.26 mmol) was added to thiol (4) (0.600 g, 3.02 mmol) dissolved in 
degassed acetonitrile (10 mL). After stirring the reaction for 5 mins acetic anhydride (0.30 mL, 3.16 
mmol), was added slowly. Thereafter, the reaction was stirred at room temperature under N2 for a 
further 90 minutes. The reaction mixture was diluted with H2O (10 mL), the pH lowered to pH 3 
using 1 M HCl and the aqueous layer extracted using EtOAc (3 x 30 mL). The combined organic 
extracts were washed with H20 (3 x 30 mL) and saturated NaHCO3 (20 mL), the solvent was removed 
under reduced pressure and the residue purified by column chromatography using mixtures of 
EtOAc and hexane to yield the product (11) as a yellow oil (0.561 g, 79%).  
Rf = 0.6 (Hexane / EtOAc = 95 / 5), 
1H NMR (400 MHz, CDCl3): δ 1.85 (2H, m, H-2), 2.34 (3H, s, H-10), 
2.48 (2H, t, J = 8.0 Hz, H-3), 2.95 (2H, t, J = 8.0 Hz, H-1), 3.69 (2H, s, H-4), 3.82 (3H, s, OMe), 6.86 (2H, 
d, J = 8.0  Hz, H-7), 7.24 (2H, d, J = 8.0 Hz, H-6); 13C NMR (100 MHz, CDCl3): δ 28.2 (C-2), 29.2 (C-3), 







S-(3-((4-Methoxyphenylmethyl)sulfinyl)propyl) ethanethioate (12) 
 
To a solution of sulfide (11) (0.420 g, 1.55 mmol) in DCM (10 mL) at -78 °C, was added m-CPBA 
(0.421 g, 77 % in H2O, 2.44 mmol) slowly. The reaction was stirred at this temperature for 45 
minutes under N2 and full conversion of the sulfide substrate was confirmed by appearance of a new 
more polar spot on TLC, at which point the reaction was quenched with 1 M NaHCO3 (10 mL). The 
aqueous layer was extracted using DCM (3 x 30 mL). The combined organic layers were washed with 
H2O (3 x 30 mL), then NaHC03 (30 mL) and dried over MgSO4. Following solvent evaporation, the 
residue was purified by column chromatography using mixtures of DCM and methanol, to afford (12) 
as a white powder (0.440 g, 99 %). 
Rf = 0.5 (Hexane / EtOAc = 20 / 80), 
1H NMR (400 MHz, CDCl3): δ 2.04 (2H, quin, J = 8.0 Hz, H-2), 2.32 
(3H, s, H-10), 2.58 (2H, m, H-3), 2.96 (2H, t, J = 8.0 Hz, H-1), 3.80 (3H, s, OMe), 3.91 (1H, d, J = 12.0 
Hz, H-4a), 3.95 (1H, d, J = 12.0 Hz, H-4b), 6.89 (2H, d, J = 8.0 Hz, H-7), 7.19 (2H, d, J = 8.0 Hz, H-6); 13C 
NMR (100 MHz, CDCl3): δ 23.2 (C-2), 28.2 (C-1), 30.7 (C-10), 49.5 (C-3), 55.5 (OMe), 57.9 (C-4), 114.6 
(C-7), 121.6 (C-5) , 131.4 (C-6), 160.0 (C-9), 161.1 (C-8).  
3-(4-Methoxybenzyl thio)-1-propyne (13)45 
 
PMBCl (0.460 g, 2.95 mmol) was added to a stirring mixture of thiourea (0.270 g, 3.55 mmol) in dry 
acetonitrile (10 mL). The mixture was refluxed for 14 hours under N2, at which point the reaction 
was cooled in an ice bath and isothiouronium salt retrieved using cold filtration washing with ice-
cold acetonitrile (50 mL). The residue was dried on the high vacuum pump to afford the crude 
isothiouronium salt (0.700 g, 91 %).  
The isothiouronium salt (0.700 g, 3.02 mmol) was added to a stirring solution of potassium 
hydroxide (0.423 g, 7.54 mmol) in degassed anhydrous methanol (10 mL) at – 20 °C. After stirring the 
reaction at this temperature for 2hrs the reaction temperature was allowed to rise to 0 °C, then 




was quenched with H2O (10 mL). The aqueous layer was extracted with EtOAc (3 x 20 mL) and then 
the combined organic extracts were washed with H2O (3 x 20 mL) and dried over MgSO4. After 
subsequent removal of solvent under reduced pressure, the residue was purified by column 
chromatography using mixtures of EtOAc and hexane to afford (13) (520 mg, 90 %) as a gold- 
coloured oil.  
Rf = 0.8 (Hexane / EtOAc = 40 / 60); IR vmax/cm-1 (CH2Cl2): 3300 (C≡C);  1H NMR (400 MHz, CDCl3):  2.36 
(1H, t, J = 6.4 Hz, 2.8 Hz, H-8), 3.11 (2H, d, J = 2.8 Hz, H-6), 3.82 (3H, s, OMe), 3.87 (2H, s, H-5), 6.89 
(2H, d, J = 8.8 Hz, H-3), 7.29 (2H, d, J = 8.8 Hz, H-2); 13C NMR (100 MHz, CDCl3): δ 18.2 (C-6), 34.6 (C-
5), 55.1 (OMe), 71.2 (C-8), 80.0 (C-7), 113.9 (C-2), 129.3 (C-4), 130.0 (C-3), 158.7 (C-1).  
(E/Z)-S-3-(4-Methoxybenzylthio)prop-1-en-yl) ethanethioate (14) 
 
Alkyne (13) (0.200 g, 1.04 mmol) was dissolved in dry toluene (5 mL) and the solution  heated to 85 
°C under N2, at which point ACCN (25.4 mg, 0.10 mmol) was added followed by the addition of 
thiolacetic acid (95.2 mg, 1.25 mmol). The reaction was stirred at 85 °C for 3 h, thereafter cooled to 
room temperature and quenched with saturated NaHCO3 (5 mL). Toluene was removed under 
reduced pressure and the residue diluted with EtOAc (10 mL). The aqueous layer was extracted using 
EtOAc (3 x 15 mL), then the combined organic fractions washed with H2O (3 x 15 mL), then brine (10 
mL) and dried over MgSO4. The solvent was removed under reduced pressure and the residue 
purified by column chromatography using mixtures of EtOAc and hexane (1-5% EtOAc) to afford (14) 
(164 mg, 59 %) as ≈ 1 : 2 mixture of E : Z isomers.  
E/Z mixture: Rf = 0.5 (Hexane / EtOAc = 90 / 10),
 IR vmax/cm-1 (CH2Cl2): 1700 (C=O), 705 (C-S) 
Z-isomer: 1H NMR (400 MHz, CDCl3): δ 2.40 (3H, s, H-1), 3.14 (2H, dd, J = 7.8 Hz, 1.0 Hz, H-5), 3.68 
(2H, s, H-6), 3.83 (3H, s, OMe), 5.89 (1H, m, H-4), 6.69 (1H, dt, J = 12.0 Hz, 1.0 Hz, H-3), 6.86 (2H, d, J 
= 9.0 Hz, H-9), 7.24 (2H, J = 9.0 Hz, H-8); 13C NMR (100 MHz, CDCl3): δ 30.8 (C-1), 33.3 (C-5), 35.3 (C-
6), 55.4 (OMe), 114.1 (C-9), 119.7 (C-3), 130.0 (C-7), 130.2 (C-4), 130.3 (C-8), 158.9 (C-10), 191.4 (C-
2). 
E-isomer: 1H NMR (400 MHz, CDCl3): δ 2.39 (3H, s, H-1), 3.12 (2H, dd, J = 7.2 Hz, 1.2 Hz, H-5), 3.67 




Hz, H-9), 7.27 (2H, d, J = 8.0 Hz, H-8) ); 13C NMR (100 MHz, CDCl3): δ 30.9 (C-1), 34.6 (C-5), 35.3 (C-6), 
55.4 (OMe), 114.1 (C-9), 119.5 (C-3), 128.7 (C-7), 129.9 (C-8), 130.5 (C-4), 158.8 (C-10), 193.0 (C-2). 
(E/Z)-9-(4-Hydroxyphenyl)-1-(4-methoxyphenyl)-2,6,7-trithianona-4-ene (15) 
 
Potassium hydroxide (0.258 g, 4.62 mmol) was added to a solution of vinyl thioacetate (15) (0.777 g, 
2.89 mmol) in methanol (15 mL) at -40 °C and the reaction was stirred for 30 mins under N2. The 
temperature was lowered to -78 °C and then thiosulfonothioate (3) (1.249 g, 4.05 mmol) in 
methanol (3 mL) was added. The reaction temperature was allowed to rise up to room temperature 
and the reaction was stirred overnight. The reaction was quenched with water (10 mL), the 
methanol removed under reduced pressure and the residue re-suspended in DCM (10 mL). The 
aqueous layer was extracted using DCM (3 x 15 mL) and the combined organic extracts were washed 
with brine (2 x 10 mL). After subsequent removal of solvent under reduced pressure the residue was 
purified by column chromatography using MeOH and DCM as eluent, to yield (15) (0.864 g, 79 %) as 
a 4 : 5 mixture of E : Z isomers. 
 E/Z mixture:  Rf = 0.4 (Hexane / EtOAc = 85 / 15), IR vmax/cm
-1
 (CHCl3): 3152 (ArOH), 663 (C-S); HRMS 
(ES) m/z: 379.0849 [M+ H] +, C19H23O2S3 requires 379.0860. 
 Z-isomer: 1H NMR (400 MHz, CDCl3): δ 2.95 (4H, m, H-5, H-6), 3.25 (2H, dd, J = 7.6 Hz, 0.8 Hz, H-2), 
3.72 (2H, s, H-1), 3.82 (3H, s, OMe), 5.05 (1H, brs, OH), 5.73 (1H, m, H-3),  6.28 (1H, dt, J = 9.2 Hz, 1.0 
Hz, H-4), 6.75 (2H, dd, J = 8.4 Hz, 4.4 Hz, H-3’), 6.87 (2H, dd, J = 8.8 Hz, 2.2 Hz, H-3”), 7.08 (2H, t, 8.4 
Hz, H-2’), 7.22 (2H, m, H-2”); 13C NMR (100 MHz, CDCl3): δ 29.5 (C-2), 34.8 (C-5) 35.6 (C-1), 40.6 (C-6), 
55.4 (OMe), 114.2 (C-3”), 115.6 (C-3’), 128.3 (C-3), 129.9 (C-2’), 130.2 (C-2”), 130.7 (C-1”), 132.0 (C-
1’)  132.4 (C-4), 154.3 (C-4’), 158.8 (C-4”). 
E-isomer: 1H NMR (400 MHz, CDCl3): δ 2.95 (4H, m, H-5 and H-6), 3.10 (2H, dd, J =7.2 Hz, 1.0 Hz, H-2), 
3.65 (2H, s, H-1), 3.82 (3H, s, OMe), 5.05 (1H, brs, OH), 5.89 (1H, m, H-3), 6.10 (1H, dt, J = 14.8 Hz, 1.2 
Hz, H-4), 6.76 (2H, dd, J = 8.4 Hz, 4.4 Hz, H-3’), 6.87 (2H, dd, J = 8.8 Hz, 2.2 Hz, H-3”),  7.08 (2H, t, 8.4 
Hz, H-2’), 7.22 (2H, m, H-2”); 13C NMR (100 MHz, CDCl3): δ 32.9 (C-2), 34.7 (C-5), 34.8 (C-1), 39.8 (C-
6), 55.4 (OMe), 114.1 (C-3’), 114.2 (C-3”), 115.5 (C-3’), 128.2 (C-3), 128.4 (C-4), 129.9 (C-2’), 130.2 (C-







The sulfide (14) (0.382 g, 1.00 mmol) was dissolved in DCM (3 mL) and the temperature lowered to  
-78 °C at which point m-cpba (0.268 g, 77 % in H2O, 1.20 mmol) was added. The reaction was stirred 
for 5 hrs under N2 at -78 °C and then quenched with 1 M NaHCO3 (5 mL). The aqueous layer was 
extracted with DCM (3 x 10 mL), the combined organic extracts washed with H2O (2 x 10 mL), 
saturated NaHCO3 (10mL) and brine (10 mL). The organic extracts were dried over MgSO4, the 
solvent removed under reduced pressure and the residue purified by column chromatography using 
EtOAc and hexane as eluent. The title compound (15) (0.234 g, 68%) was isolated as a 1 : 1 mixture 
of E : Z isomers as a light brown oil.  
Rf = 0.6 (Hexane / EtOAc = 40 / 60), IR vmax/cm
-1
 (CHCl3): 3152 (ArOH), 1325 (S=O), 663 (C-S); HRMS 
(ES) m/z: 393.0646 [M- H]+, C19H21O3S3 requires 393.0653. 
Z-isomer: 1H NMR (400 MHz, CDCl3): δ 2.91 (4H, m, H-5 and H-6), 3.48 (1H, ddd, J = 13.5 Hz, 7.5 Hz, 
0.9 Hz,, H-2a), 3.54 (1H, ddd, J = 13.5 Hz, 7.5 Hz, 0.9 Hz, H-2b), 3.80 (3H, s, OMe), 3.94 (2H, s, H-1), 
5.72 (1H, m, H-3), 6.57 (1H, dt, J = 9.6 Hz, 0.9 Hz, H-4), 6.75 (2H, dd, J = 8.8 Hz, 1.4 Hz, H-3’), 6.90 (2H, 
dd, J = 9.0 Hz, 0.8 Hz, H-3”), 7.02 (2H, m, H-2’), 7.20 (2H, d, J = 9.0 Hz, H-2”); 13C NMR (100 MHz, 
CDCl3): δ 34.8 (C-5), 40.8 (C-6), 49.6 (C-2), 55.5 (OMe), 57.0 (C-1), 114.7 (C-3”), 115.7 (C-3’), 118.3 (C-
3), 121.6 (C-1”), 129.9 (C-2’), 131.0 (C-1’), 131.4 (C-2”), 138.9 (C-4), 154.9 (C-4’), 160.1 (C-4”).  
E-isomer: 1H NMR (400 MHz, CDCl3): δ 2.91 (4H, m, H-5 and H-6), 3.32 (1H, ddd, J = 13.2 Hz, 8.1 Hz, 
0.9 Hz, H-2a), 3.44 (1H, ddd, J = 13.2 Hz, 8.1 Hz, 0.9 Hz, H-2b), 3.80 (3H, s, OMe), 3.96 (2H, s, H-1), 
5.83 (1H, m, H-3), 6.25 (1H, dt, J = 14.7 Hz, 0.9 Hz, H-4), 6.76 (2H, dd, J = 8.8 Hz, 1.0 Hz, H-3’), 6.90 
(2H, dd, J = 9.0 Hz, 0.8 Hz, H-3”), 7.01 (2H, m, H-2’), 7.23 (2H, d, J = 9.0 Hz, H-2”); 13C NMR (100 MHz, 
CDCl3): δ 34.8 (C-5), 40.4 (C-6), 53.0 (C-2), 55.5 (OMe), 56.4 (C-1), 114.7 (C-3”), 115.7 (C-3’), 116.3 (C-










TBDMSCl (1.53 g, 13.5 mmol) in DMF (5 mL) was added dropwise to a stirring solution of butane-1,4-
diol (1.22 g, 13.5 mmol) and imidazole (1.72 g, 25.2 mmol) in DMF (20 mL),. The reaction was 
allowed to proceed at room temperature under N2 for 3 h at which point the reaction was quenched 
with H2O (40 mL). The aqueous layer was extracted using EtOAc (40 mL x 3) and the combined 
organic extracts were washed with H2O (40 mL x 10) to remove the DMF. The extracts were dried 
over MgSO4, the solvent removed under reduced pressure and the residue purified by column 
chromatography using mixtures of EtOAc and hexane to yield a colourless liquid (16) (1.92 g, 69 %). 
Rf = 0.4 (Hexane / EtOAc = 30 / 60),
 IR vmax/cm-1 (CH2Cl2): 3400 (O-H), 1099 (C-0); 1H NMR (400 MHz, 
CDCl3): δ 0.00 (6H, s, 2 x Si(CH3)), 0.84 (9H, s, Si(CH3)3), 1.57 (4H, m, H-2 and H-3), 3.06 (1H, brs, OH), 
3.58 (4H, m, H-1 and H-4); 13C NMR (100 MHz, CDCl3): δ -5.20 (SiCH3), 18.3 (SiCMe3), 26.0 (SiC(CH3)3), 
29.8 (C-3), 30.0 (C-2), 62.6 (C-4), 63.3 (C-1).  
4-((tert-Butyldimethylsilyl)oxy)butyl 2-chloroacetate (17) 
 
Alcohol (16) (1.55 g, 8.72 mmol) and triethylamine (2.50 mL, 17.9 mmol) were dissolved in dry DCM 
(20 mL), the temperature was lowered to -20 °C then chloroacetyl chloride (1.03 mL, 10.5 mmol) was 
added via a syringe. The reaction was allowed to proceed for 10 min under N2 and then quenched 
with 0.25 M NaHCO3 (10 mL). The aqueous layer was extracted with DCM (3 x 20 mL), the combined 
organic fractions were washed with H2O (3 x 10 mL) and then brine (10 mL). The crude residue was 
dried over MgSO4, the solvent removed under reduced pressure and the residue purified by column 
chromatography using mixtures of EtOAc and hexane. The title compound (17) was isolated as a 
colourless oil (1.77 g, 72 %). 
 Rf = 0.85 (Hexane / EtOAc = 70 / 30),
 IR vmax/cm-1 (CH2Cl2): 1755 (C=0), 1098 (C-0); 1H NMR (400 MHz, 
CDCl3) : δ 0.04 (6H, s, 2 x Si(CH3)), 0.89 ( 9H, s, Si(CH3)3), 1.57 (2H, m, H-5), 1.72 (2H, m, H-4), 3.63 
(2H, t, J = 8.2 Hz, H-6), 4.04 (2H, s, H-1), 4.21 (2H, t, J = 8.8 Hz, H-3); 13C NMR (100 MHz, CDCl3): δ -








Phenol (15) (150 mg, 0.40 mmol) and potassium carbonate (109 mg, 0.80 mmol) in acetonitrile (3 
mL) were stirred for 10 min and the chloroacetate (17) (222 mg, 0.80 mmol) was added. The reaction 
was stirred at 40 °C under N2 for 72 h, at which point the solvent was removed under reduced 
pressure and the residue suspended in EtOAc (10 mL) and H2O (10 mL). The aqueous layer was 
extracted using EtOAc (3 x 10 mL), the combined organic extracts washed with H2O (3 x 10 mL), brine 
(10 mL) and dried over MgSO4. The solvent was removed under reduced pressure and the residue 
purified by column chromatography using EtOAc and hexane as the eluents. The title compound (18) 
was isolated as a yellow oil (113 mg, 45 %) as an E: Z mixture (7: 5).  
Rf = 0.5 (Hexane / EtOAc = 85 / 15),
 IR vmax/cm-1 (CH2Cl2): 1750 (C=0), 1099 (C-0), 705 (C-S);  
Z-isomer: 1H NMR (400 MHz, CDCl3): δ 0.05 (6H, s, 2 x Si(CH3)), 0.91 (9H, s, Si(CH3)3), 1.55 (2H, m, H-
8’), 1.73 (2H, m, H-9’), 2.93 (4H, s, H-5 and H-6), 3.24 (2H, d, J = 7.6 Hz, H-2), 3.62 (2H, m, H-10’), 3.68 
(2H, s, H-1), 3.79 (3H, s, OMe), 4.23 (2H, t, J = 6.6 Hz, H-7’), 4.59 (2H, s, H-5’), 5.71 (1H, dt, J = 9.2 Hz, 
7.6 Hz, H-3), 6.24 (1H, dt, J = 9.2 Hz, 1.2 Hz, H-4), 6.84 (4H, m, H-3’ and H-3”), 7.10 (2H, t, J = 7.2 Hz, 
H-2’), 7.24 (2H, d, J = 8.8 Hz, H-2”); 13C NMR (100 MHz, CDCl3): δ -5.28 (SiCH3), 18.3 (SiC), 25.4 (C-8’), 
26.1 (SiC(CH3)3), 29.2 (C-9’), 29.6 (C-2 and C-5), 34.9 (C-1),  40.6 (C-6), 55.4 (OMe), 62.6 (C-10’), 65.4 
(C-7’), 65.8 (C-5’), 114.2 (C-3”), 115.0 (C-3’), 128.5 (C-3), 129.8 (C-2’), 130.2 (C-2”), 132.3 (C-4), 133.2 
(C-1’), 156.8 (C-4’), 158.9 (C-4”), 170.0 (C-6’).  
E-isomer: 1H NMR (400 MHz, CDCl3): δ 0.05 (6H, s, 2 x Si(CH3)), 0.91 (9H, s, Si(CH3)3), 1.55 (2H, m, H-
8’), 1.73 (2H, m, H-9’), 2.93 (4H, s, H-5 and H-6), 3.09 (2H, dd, J = 8.4 Hz, 1.0 Hz, H-2), 3.62 (4H, m, H-
1 and H-10’), 3.79 (3H, s, OMe), 4.23 (2H, t, J = 6.6 Hz, H-7’), 4.59 (2H, s, H-5’), 5.89 (1H, m, H-3), 6.09 
(1H, dt, J = 14.4 Hz, 1.0 Hz, H-4), 6.84 (4H, m, H-3’ and H-3”), 7.10 (2H, t, J = 7.2 Hz, H-2’), 7.21 (2H, d, 
J = 8.8 Hz, H-2”); 13C NMR (100 MHz, CDCl3): δ -5.28 (SiCH3), 18.3 (SiC), 25.4 (C-8’), 26.1 (SiC(CH3)3), 
29.2 (C-9’), 29.6 (C-5), 33.0 (C-2), 34.8 (C-1), 39.8 (C-6), 55.4 (OMe), 62.6 (C-10’), 65.4 (C-7’), 65.8 (C-
5’), 114.2 (C-3”), 115.0 (C-3’), 128.2 (C-4), 128.2 (C-3), 129.8 (C-2’), 130.2 (C-2”), 133.2 (C-1’), 156.8 





6.3 Biological Experimental 
Cell Culture 
The oesophageal cancer cell-line was derived from a biopsy of primary oesophageal squamous cell 
carcinoma of South African origin. WHCO1 cells were incubated at 37 °C in a humidified atmosphere 
under 5 % CO2 and cultured in Dulbecco’s Modified Eagle Medium (DMEM) containing 10 % Fetal 
bovine serum (FBS) and 1 % penicillin-streptomycin. Cells were grown in 150 mm e plates and split 1: 
12 every four days. The splitting procedure, briefly, involved removing cell media and washing cells 
with 10 mL PBS (Phosphate buffer saline, pH 7.4). Cells were then incubated in trypsin (3 mL) at 37 ° 
C for 1-2 min. Trypsin was deactivated by adding media (3 mL). Thereafter detached cells were 
transferred to a sterile 12 mL conical tube containing media (3 mL) and centrifuged at 40 000 rpm 
for 4 min. Upon removal of the media-trypsin solution, the cells were quickly re-suspended in media 
(6 mL). 
MTT Assay 
On day 1, WHCO1 cells were seeded in 96-well plates, at 2500 cells per well suspended in DMEM (90 
μL). Cells were allowed to attach and recover overnight 
On day 2, a 150 mM stock solution of the compound in high purity DMSO (99.9%) was prepared. The 
solutions were sonicated at 37 °C for 10 min to ensure complete dissolution. The stock was then 
further diluted in DMSO to give the following series of concentrations: 0, 0.3, 0.58, 1.17, 2.34, 4.68, 
9.38, 18.75, 37.5, 75.0 and 150 mM. The solutions were then subjected to a further 100-fold dilution 
into media. Thereafter, 10 µL of the compound solution was added to the cells, to give final 
concentrations of 0, 0.3, 0.58, 1.17, 2.34, 4.68, 9.38, 18.75, 37.5, 75.0 and 150 µM in the cells and  
final DMSO concentrations of 0.1 %. The negative controls were cells treated with 0.1 % DMSO alone 
and cells treated with media alone. All experiments were performed in quadruplicate. The cells were 
then incubated with the compound for 48 h.  
On day 4, 10 µL of MTT (5mg/mL) solution was added to each well and the cells incubated for a 
further 4 h. Thereafter 100 µL of solubilization reagent (10% SLS in 0.01 M HCl) was added to each 
well and the cells incubated overnight.  
On day 5, the absorbance was measured at 595 nm using the Multiskan FC multi-well reader 
(Thermo Scientific). The background media reading was subtracted using readings from wells 
containing media and reagents only (no cells). The spectrophotometric data was analysed using 




determined. Each compound IC50 is calculated as the mean of at least three independent 
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